Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

STNLOGON timed out

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * * Welcome to STN International
                                                     * * * * * * * * * *
NEWS 1
                 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26
                 MARPAT enhanced with FSORT command
         NOV 26
                 CHEMSAFE now available on STN Easy
NEWS
NEWS 5
        NOV 26
                 Two new SET commands increase convenience of STN
                  searching
NEWS 6
         DEC 01
                 ChemPort single article sales feature unavailable
     7 DEC 12
                 GBFULL now offers single source for full-text
NEWS
                  coverage of complete UK patent families
NEWS 8 DEC 17
                 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06
                 The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo
                 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
NEWS 10 JAN 07
                  Classification Data
NEWS 11 FEB 02
                 Simultaneous left and right truncation (SLART) added
                 for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
GENBANK enhanced with SET PLURALS and SET SPELLING
         FEB 02
NEWS 12
NEWS 13
         FEB 06
                 Patent sequence location (PSL) data added to USGENE
NEWS 14
         FEB 10
                 COMPENDEX reloaded and enhanced
NEWS 15
         FEB 11
                 WTEXTILES reloaded and enhanced
NEWS 16
        FEB 19
                 New patent-examiner citations in 300,000 CA/CAplus
                  patent records provide insights into related prior
NEWS 17 FEB 19
                  Increase the precision of your patent queries -- use
                  terms from the IPC Thesaurus, Version 2009.01
NEWS 18 FEB 23
                 Several formats for image display and print options
                  discontinued in USPATFULL and USPAT2
NEWS 19
         FEB 23
                 MEDLINE now offers more precise author group fields
                  and 2009 MeSH terms
NEWS 20 FEB 23
                 TOXCENTER updates mirror those of MEDLINE - more
                  precise author group fields and 2009 MeSH terms
                 Three million new patent records blast AEROSPACE into
NEWS 21 FEB 23
                  STN patent clusters
NEWS 22 FEB 25
                 USGENE enhanced with patent family and legal status
                  display data from INPADOCDB
NEWS 23
                  INPADOCDB and INPAFAMDB enhanced with new display
         MAR 06
                  formats
NEWS 24 MAR 11
                 EPFULL backfile enhanced with additional full-text
                  applications and grants
NEWS 25 MAR 11
                 ESBIOBASE reloaded and enhanced
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
```

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 23:01:24 ON 15 MAR 2009

=> file req

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

ENTRY SESSION 0.22

FILE 'REGISTRY' ENTERED AT 23:02:04 ON 15 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the  ${\tt ZIC/VINITI}$  data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2009 HIGHEST RN 1120564-02-4 DICTIONARY FILE UPDATES: 13 MAR 2009 HIGHEST RN 1120564-02-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting  ${\tt SmartSELECT}$  searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\Stnexp\Queries\10563471.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 23:02:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 54 TO ITERATE

100.0% PROCESSED 54 ITERATIONS 6 ANSWERS SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 640 TO 1520 PROJECTED ANSWERS: 6 TO 266 L2 6 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 23:02:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 970 TO ITERATE

100.0% PROCESSED 970 ITERATIONS 172 ANSWERS

SEARCH TIME: 00.00.01

L3 172 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'CAPLUS' ENTERED AT 23:02:41 ON 15 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Mar 2009 VOL 150 ISS 12 FILE LAST UPDATED: 13 Mar 2009 (20090313/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 1498 L3

=> file reg

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.50 186.60

FILE 'REGISTRY' ENTERED AT 23:03:30 ON 15 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2009 HIGHEST RN 1120564-02-4 DICTIONARY FILE UPDATES: 13 MAR 2009 HIGHEST RN 1120564-02-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and

predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\Stnexp\Queries\10563471excludedcompound.str

STRUCTURE UPLOADED

=> s 15

SAMPLE SEARCH INITIATED 23:05:00 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -

100.0% PROCESSED 3 ANSWERS 54 ITERATIONS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\* BATCH \*\*COMPLETE\*\* PROJECTED ITERATIONS: 640 TO 1520 PROJECTED ANSWERS: 3 TO 163

3 SEA SSS SAM L5

=> s 15 full

FULL SEARCH INITIATED 23:05:04 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 970 TO ITERATE

100.0% PROCESSED 970 ITERATIONS 68 ANSWERS SEARCH TIME: 00.00.01

1.7 68 SEA SSS FUL L5

=> d his

(FILE 'HOME' ENTERED AT 23:01:24 ON 15 MAR 2009)

FILE 'REGISTRY' ENTERED AT 23:02:04 ON 15 MAR 2009

STRUCTURE UPLOADED T.1

6 S L1 L2

L3172 S L1 FULL

FILE 'CAPLUS' ENTERED AT 23:02:41 ON 15 MAR 2009

1498 S L3

FILE 'REGISTRY' ENTERED AT 23:03:30 ON 15 MAR 2009

STRUCTURE UPLOADED 1.5

L6 3 S L5

68 S L5 FULL

=> s 13 not 17

104 L3 NOT L7 L8

=> file caplus

COST IN U.S. DOLLARS TOTAL SINCE FILE ENTRY SESSION FULL ESTIMATED COST 187.32 373.92

FILE 'CAPLUS' ENTERED AT 23:05:53 ON 15 MAR 2009 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

## 10/563,471

strictly prohibited.

FILE COVERS 1907 - 15 Mar 2009 VOL 150 ISS 12 FILE LAST UPDATED: 13 Mar 2009 (20090313/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

L9 79 T.8

=> d bib abs hitstr 1-9 19

- T.9 ANSWER 1 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2008:1377173 CAPLUS
- 150:10839 DN
- Novel medical application of puerarin and its derivatives as selective TT COX-2 inhibitor
- ΙN Yang, Dajian; Zhong, Guoyue; Xu, Jiahong; Zhang, Yi; Li, Henghua; Huang, Xiaoping
- Chongqing Academy of Chinese Materia Medica, Peop. Rep. China PA
- Faming Zhuanli Shenqing Gongkai Shuomingshu, 10pp. SO CODEN: CNXXEV
- DT Patent
- LΑ Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 101301303	A	20081112	CN 2008-10069880	20080625
PRAI	CN 2008-10069880		20080625		

- The invention relates to the medical application of puerarin and its derivs. as selective  ${\rm COX-2}$  inhibitor for preventing and treating osteoarthritis, rheumatic and rheumatoid arthritis, gouty arthritis, hepatitis, conjunctivitis, myocarditis, tumor- and diabetes-induced secondary inflammation, influenza, and trauma-associated pain. 2889-07-8P 882979-98-8P
- - RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
    - (novel medical application of puerarin and its derivs. as selective COX-2 inhibitor)
- 2889-07-8 CAPLUS RN
- CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-4)tetra-O-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

 $4H-1-Benzopyran-4-one, \ 7-(acetyloxy)-3-(4-hydroxyphenyl)-8-(2,3,4,6-tetra-1)-8-(2,$  $O-acetyl-\beta-D-glucopyranosyl)-$  (CA INDEX NAME)

Absolute stereochemistry.

- L9 ANSWER 2 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2008:455298 CAPLUS
- DN 149:216373
- TI Effect of acetylpuerarin on apoptosis and apoptosis-regulating genes induced by angiotensin II in vascular endothelial cells
- AU Feng, Yueqiu; Wang, Shumei; Zhang, Xiumei
- CS Department of Epidemiology, School of Public Health, Shandong University, Jinan, Shandong Province, 250012, Peop. Rep. China
- SO Zhongguo Shenghua Yaowu Zazhi (2007), 28(1), 11-14 CODEN: ZSYZFP; ISSN: 1005-1678
- PB Zhongguo Shenghua Yaowu Zazhi Bianjibu
- DT Journal
- LA Chinese
- The effect of angiotensin II in different concns. and at different action time on apoptosis ratio and the expression of Fas, Bcl-2 in vascular endothelial cells was investigated, and the effect of acetylpuerarin on apoptosis was revealed. Flow cytometer was used to measure the apoptosis ratio and the expression of Fas, Bcl-2 induced by angiotensin II in different concns. and at different action time of acetylpuerarin. Apoptosis ratio and the expression of Fas, Bcl-2 were induced and increased by angiotensin II with the increase of concns. and action time. Acetylpuerarin had some effect on apoptosis ratio and the expression of Fas, Bcl-2, which were induced by angiotensin II. Apoptosis ratio and the expression of Fas, Bcl-2 were induced and increased by angiotensin II with the increase of the concns. and the different action time. Acetylpuerarin reduces the apoptosis ratio and the expression of Fas and Bcl-2 in vascular endothelial cells.
- IT 2889-07-8
  - RL: PAC (Pharmacological activity); BIOL (Biological study) (effect of acetylpuerarin on apoptosis and apoptosis-regulating genes induced by angiotensin II in vascular endothelial cells)
- RN 2889-07-8 CAPLUS
- CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-tetra-0-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME)

## 10/563,471

- L9 ANSWER 3 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2008:397912 CAPLUS
- DN 148:456492
- TI Compound effervescent formulation containing Radix Puerariae extract for preventing and treating osteoporosis, cardiovascular diseases and climacteric syndrome
- IN Zhao, Hongyi; Xu, Pinghui
- PA Zhengzhou Biocaro Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China
- SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 7pp. CODEN: CNXXEV
- DT Patent
- LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 101147754	A	20080326	CN 2006-10107067	20060919
PRAI	CN 2006-10107067		20060919		

- AB The title formulation can be tablet or granule containing Radix Puerariae extract (daidzein, soybean glucoside, puerarin and puerarin-7-xyloside), physiol. active substances (vitamin, amino acid, mineral element and/or L-carnitine), and medical adjuvant. The tablet or granule may be used as medicine for preventing and treating osteoporosis, cardiovascular diseases and climacteric syndrome, and as health food for delaying aging, plumping breasts, nursing ovaries, improving face luster, and expelling macula for adult women.
- IT 303114-83-2
  - RL: COS (Cosmetic use); FFD (Food or feed use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compound effervescent formulation containing Radix Puerariae extract for preventing and treating osteoporosis, cardiovascular diseases and climacteric syndrome)
- RN 303114-83-2 CAPLUS
- CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-7-( $\beta$ -D-xylopyranosyloxy)- (CA INDEX NAME)

- L9 ANSWER 4 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2008:171637 CAPLUS
- DN 148:331259
- TI Puerarin as an antioxidant fluorescence probe
- AU Tian, Yu-Xi; Han, Rui-Min; Wang, Peng; Wu, Yi-Shi; Zhang, Jian-Ping; Skibsted, Leif H.
- CS Beijing National Laboratory for Molecular Science (BNLMS), State Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100080, Peop. Rep. China
- SO Chemical Physics Letters (2008), 452(4-6), 253-258 CODEN: CHPLBC; ISSN: 0009-2614
- PB Elsevier B.V.
- DT Journal
- LA English

## 10/563,471

Diphenolic isoflavonoid puerarin fluoresces in aqueous solution with maximal intensity at pH 8.5 ( $\Phi$ fl = 0.042,  $\tau$ fl = 1.91 ns). For acidic solns., weak fluorescence is attributed to fluorescent 7-monophenolate formed via excited-state deprotonation of neutral puerarin. For pH > 8.5, fluorescence decreases monotonically with an unchanged lifetime, suggesting that excited-state acidity of 4'-hydroxyl remains similar to the ground-state one, and that the diphenolate is non-fluorescent. The crucial role of A-ring 7-phenolate for fluorescence of puerarin is substantiated by absence (presence) of fluorescence for the 7-propylpuerarin (4'-propylpuerarin). Puerarin and its derivs. with the unusual properties may be explored to be antioxidant fluorescence probes. 933984-63-5, 4'-O-Propylpuerarin 1010691-25-4, Puerarin monoanion 1010691-26-5, Puerarin dianion 1010691-27-6, 4'-O-Propylpuerarin monoanion RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process) (puerarin as an antioxidant fluorescence probe) 933984-63-5 CAPLUS  $\texttt{4H-1-Benzopyran-4-one, 8-\beta-D-glucopyranosyl-7-hydroxy-3-(4-benzopyranosyl-7-hydroxy-3-(4-be$ CN propoxyphenyl) - (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

RN 1010691-26-5 CAPLUS CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-, ion(2-) (CA INDEX NAME)

RN 1010691-27-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-(4-propoxyphenyl)-, ion(1-) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 5 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2008:118631 CAPLUS
- DN 148:379808
- TI Radical Dynamics of Puerarin as Revealed by Laser Flash Photolysis and Spin Density Analysis
- AU Tian, Yu-Xi; Han, Rui-Min; Fu, Li-Min; Zhang, Jian-Ping; Skibsted, Leif H.
- CS Beijing National Laboratory for Molecular Science (BNLMS), State Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100080, Peop. Rep. China
- SO Journal of Physical Chemistry B (2008), 112(7), 2273-2280 CODEN: JPCBFK; ISSN: 1520-6106
- PB American Chemical Society
- DT Journal
- LA English
- AB Puerarin, a C-glycoside of daidzein, forms upon direct photoexcitation in acetonitrile an excited-state with a lifetime of 4.2 μs assigned by oxygen quenching and sensitized formation of triplet zeaxanthin as a triplet and phenoxyl radicals of ms lifetime insensitive to oxygen and with spin d. delocalized over the ACB isoflavonoid ring system, [ACB]•, as shown by laser flash photolysis and theor. spin d. calcns. Photoexcitation of A-ring 7-phenolate puerarin yields a [AC]• radical, which converts into the [ACB]• radical with a rate constant of 3.6 + 105 s-1 in 5% methanolic acetonitrile in a process triggered by B-ring deprotonation (4'-phenol). For the 7-phenolate with the 4'-phenol derivatized to yield a Pr anisole, no rearrangement of the initially formed [AC]• radical was observed With the A-ring phenol derivatized, the 7-propyl-4'-phenolate forms a radical with spin d. delocalized over

the CB ring system, [CB] •, together with a minor fraction of [ACB] • due to Pr radical dissocns. confirmed by BDE-calcns. Dianionic puerarin forms initially the [ACB] • radical, which is converted into the [CB] • radical in a slower process (1.6 + 104 s-1) assigned to 7-methylation. The radical dynamics is discussed in relation to puerarin/carotenoid antioxidant synergism at water/lipid interphases.

II 623900-91-4 933984-62-4 933984-63-5
RL: PRP (Properties)
 (radical dynamics of puerarin as revealed by laser flash photolysis and spin d. anal.)

RN 623900-91-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-7-propoxy-3-(4-propoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 933984-62-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-3-(4-hydroxyphenyl)-7propoxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 933984-63-5 CAPLUS CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-(4-propoxyphenyl)- (CA INDEX NAME)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

2007:1486576 CAPLUS AN

148:322745 DN

TΙ Reducing the levels of ET-1 and IL-6 in ischemia-reperfusion injury rats with hydroxyethylpuerarin

ΑU Wang, Ziying; Wei, Xinbing; Zhang, Bin; Sun, Ru; Sun, Xia; Zhong, Ying; Zuo, Chunxu; Zhang, Xiumei

CS School of Medicine, Shandong University, Jinan, Shandong Province, 250012, Peop. Rep. China

SO Zhongguo Shenghua Yaowu Zazhi (2006), 27(5), 280-282 CODEN: ZSYZFP; ISSN: 1005-1678

PB Zhongquo Shenghua Yaowu Zazhi Bianjibu

DT Journal

Chinese ΤιA

The effects of hydroxyethylpuerarin on the levels of endothelin-1 (ET-1) AB and interleukin 6 (IL-6) in focal brain ischemia-reperfusion injury rats were investigated. Rats were divided into 6 groups randomly: sham-operate group, ischemia-reperfusion group, hydroxyethylpuerarin 15 mg/kg, 30 mg/kg, 60 m/kg groups and nimodipine 0.2 mg/kg group. Rats were prepared with a model of focal brain ischemic injury by middle cerebral artery occlusion (MCAO), and then recovered perfusion by pulling out the suture after one hour. Each animal received drugs twice a day. Forty-eight hours after ischemia followed by  $48\ h$  reperfusion, the ET-1 and IL- 6levels in both blood and brain tissues were significantly increased. Compared with ischemia-reperfusion group, these levels were significantly decreased in all hydroxyethylpuerarin-treated groups. Hydroxyethylpuerarin could protect neuronal injury induced by focal brain ischemia-reperfusion, probably through decreasing the synthesis and release of ET-1 or inflammatory reaction induced by some cytokines, such as IL-6.

ΤТ 240131-05-9

RL: BSU (Biological study, unclassified); BIOL (Biological study) (reducing the levels of ET-1 and IL-6 in ischemia-reperfusion injury rats with hydroxyethylpuerarin) 240131-05-9 CAPLUS

RN

4H-1-Benzopyran-4-one,  $8-\beta-D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-hydroxyethoxy]$ CN(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

- L9 ANSWER 7 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:1422609 CAPLUS
- DN 148:321805
- TI Study on the interaction of bovine serum albumin with puerarin and its derivatives
- AU Qu, Ling-Bo; Wang, Ling; Chen, Xiao-Lan; Yuan, Jin-Wei; Yang, Ran; Li, Ping
- CS Department of Chemistry, Anyang Normal College, Anyang, 455002, Peop. Rep. China
- SO Huaxue Xuebao (2007), 65(21), 2417-2422 CODEN: HHHPA4; ISSN: 0567-7351
- PB Huaxue Xuebao Bianjibu
- DT Journal
- LA Chinese
- AB In the paper, two new phosphorylated isoflavones of puerarin were successfully obtained by a modified Atheron-Todd reaction. Further, the interactions of bovine serum albumin (BSA) and puerarin or its phosphorylated products were studied under physiol. pH by fluorescence spectroscopy. The results showed that puerarin and its phosphorylated products all could form a non-covalent complex with BSA, while the interactions of the phosphorylated isoflavones with BSA were weaker than puerarin. The quenching mechanisms of them with BSA were suggested as a static quenching process, and the binding force was mainly a hydrophobic force. The distances between BSA and puerarin and its phosphorylated isoflavones were less than 7 nm according to the theory of the Forster energy transference. The relationship between the mol. structures of these compds. and the binding ability of them with BSA was preliminarily discussed, and the quenching consts. in the presence of various metal ions were also explored.
- IT 913627-26-6P 1010820-83-3P
  - RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
  - (interaction of bovine serum albumin with puerarin and its derivs.)
- RN 913627-26-6 CAPLUS
- CN 4H-1-Benzopyran-4-one, 7-[(diethoxyphosphinyl)oxy]-8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)- (CA INDEX NAME)

RN 1010820-83-3 CAPLUS

CN Phosphoric acid,  $8-\beta-D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl bis(1-methylethyl) ester (CA INDEX NAME)$ 

- L9 ANSWER 8 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:1382104 CAPLUS
- DN 148:206305
- TI Neuroprotective effects of hydroxyethylpuerarin against focal cerebral ischemia-reperfusion in rats
- AU Wang, Zi-Ying; Wei, Xin-Bing; Chen, Lin; Liu, Ping; Wang, Li-Xiang; Zhang, Bin; Sun, Xia; Zhang, Xiu-Mei
- CS Institute of Pharmacology, School of Medicine, Shandong University, Jinan, Shandong, 250012, Peop. Rep. China
- SO Chinese Journal of Physiology (Taipei, Taiwan) (2007), 50(5), 211-216 CODEN: CJPHDG; ISSN: 0304-4920
- PB Chinese Physiological Society
- DT Journal
- LA English
- Our present study was performed to investigate whether hydroxyethylpuerarin (HEP) has a neuroprotective effect on brain injury after focal cerebral ischemia/reperfusion by middle cerebral artery occlusion (MCAO) in adult male Wistar rats. Animals were subjected to one hour of middle cerebral artery occlusion and 48 h of reperfusion with the pretreatment of drugs (HEP 15, 30, 60 mg/kg or nimodipine 0.4 mg/kg i.v.) or vehicle. The behavioral tests were used to evaluate the damage to central nervous system. The percentage of brain infarct area was assessed in the brain slices stained with 2% solution of 2, 3, 5-triphenyl tetrazolium chloride (TTC). The pathol. histol. changes were observed by H&E staining and the occurrence of apoptosis was determined by flow cytometry. The results showed that pretreatment with HEP at doses of 15, 30, 60 mg/kg exhibited significant neuroprotective effects on rats against focal cerebral ischemia-reperfusion injury by markedly decreasing neurol. deficit scores and the percentage of infarct area, reducing necrosis and apoptosis of neurons. All these findings suggest that HEP might provide

neuroprotection against focal cerebral ischemia/reperfusion injury probably through its antioxidant and anti-inflammatory property.

IT 240131-05-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydroxyethylpuerarin exhibited neuroprotective effects by decreasing neurol. deficit score, infarct area, necrosis and apoptosis in cortex and hippocampus of rat with cerebral ischemia-reperfusion injury)

RN 240131-05-9 CAPLUS

CN 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 9 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:1369736 CAPLUS
- DN 148:134985
- TI Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms
- AU Joseph, Tiby B.; Wang, Stephen W. J.; Liu, Xing; Kulkarni, Kaustubh H.; Wang, Jingrong; Xu, Haiyan; Hu, Ming
- CS Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77030, USA
- SO Molecular Pharmaceutics (2007), 4(6), 883-894 CODEN: MPOHBP; ISSN: 1543-8384
- PB American Chemical Society
- DT Journal
- LA English
- The authors characterized the in vitro glucuronidation of prunetin, a AB prodrug of genistein that is a highly active cancer prevention agent. Metabolism studies were conducted using expressed human UGT isoforms and microsomes/S9 fractions prepared from intestine and liver of rodents and humans. The results indicated that human intestinal microsomes were more efficient than liver microsomes in glucuronidating prunetin, but rates of metabolism were dependent on time of incubation at  $37^{\circ}$ . Human liver and intestinal microsomes mainly produced metabolite 1 (prunetin-5-0-glucuronide) and metabolite 2 (prunetin-4'-0-glucuronide), resp. Using 12 human UGT isoforms, the authors showed that UGT1A7, UGT1A8, and UGT1A9 were mainly responsible for the formation of metabolite 1, whereas UGT1A1, UGT1A8, and UGT1A10 were mainly responsible for the formation of metabolite 2. This isoform-specific metabolism was consistent with earlier results obtained using human liver and intestinal microsomes, as the former (liver) is UGT1A9-rich whereas the latter is UGT1A10-rich. Surprisingly, the authors found that the thermostability of the microsomes was isoform- and organ-dependent. For example, human liver microsomal UGT activities were much more heat-stable (37°) than intestinal microsomal UGT activities, consistent with the finding that human UGT1A9 is much more thermostable than human UGT1A10 and UGT1A8. The organ-specific thermostability profiles were also evident in rat microsomes and mouse S9 fractions, even though human intestinal glucuronidation of prunetin differs significantly from rodent intestinal

glucuronidation. In conclusion, prunetin glucuronidation is species-, organ-, and UGT-isoform-dependent, all of which may be impacted by the thermostability of specific UGT isoforms involved in the metabolism

TT 1001078-71-2

RL: BSU (Biological study, unclassified); BIOL (Biological study) (disposition of flavonoids via enteric recycling and characterization of prunetin quucuronidation across species, organs, and UGT isoforms)

RM 1001078-71-2 CAPLUS

L-Gulonic acid, 2,6-anhydro-6-C-[5-hydroxy-3-(4-hydroxyphenyl)-7-methoxy-4-CN oxo-4H-1-benzopyran-8-yl]-, (6S)- (CA INDEX NAME)

Absolute stereochemistry.

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 24 ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d bib abs hitstr 10-79 19
```

- L9 ANSWER 10 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- 2007:1156770 CAPLUS AN

148:68979 DN

- Effect of hydroxyethylpuerarin on  $\beta$ -adrenergic receptor TΙ
- ΑU Pan, Yan; Xu, Hongyan; Zhang, Xiumei
- School of Medicine, Shandong University, Jinan, Shandong Province, 250012, CS Peop. Rep. China
- SO Zhongguo Shenghua Yaowu Zazhi (2006), 27(3), 145-147 CODEN: ZSYZFP; ISSN: 1005-1678
- PВ Zhongguo Shenghua Yaowu Zazhi Bianjibu
- DT Journal
- LA Chinese
- Hydroxyethylpuerarin (compound N-2035) is modified in structure from puerarin which is extracted from Chinese traditional medicinal plant, R. Puerariae. This study ws to investigate effect of hydroxyethylpuerarin on adrenergic receptors. The models of isolated rabbit aortic strips and isolated hearts were used to investigate the effect of hydroxyethylpuerarin on  $\alpha$  and  $\beta\text{--adrenoceptors.}$ Hydroxyethylpuerarin decreased the ranges of heart-tension curves and made the frequency slow. The effects were similar to propranolol. Hydroxyethylpuerarin could not obviously inhibit the contraction of the aortic strips induced by noradrenaline. Hydroxyethylpuerarin can block  $\beta\text{--adrenoceptor}$  on myocardium but has no obvious effect on  $\alpha$ -adrenoceptor on vessels.
- 240131-05-9
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (effect of hydroxyethylpuerarin on  $\beta$ -adrenergic receptor)
- 240131-05-9 CAPLUS
- CN 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

L9 ANSWER 11 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:1069253 CAPLUS

DN 149:10189

TI Synthesis of tritium-labeled puerarin - a potential antidipsotropic agent

AU Lee, D. Y. W.; Ji, X. S.; Zhang, X.

CS Department of Bio-Organic and Natural Products, Mclean Hospital, Harvard Medical School, Belmont, MA, 02478, USA

SO Journal of Labelled Compounds and Radiopharmaceuticals (2007), 50(8), 702-705

CODEN: JLCRD4; ISSN: 0362-4803

PB John Wiley & Sons Ltd.

DT Journal

LA English

GT

Puerarin (8- $\beta$ -D-Glucopyranosyl-4'-7-dihydroxyisoflavone, NPI-031G) is the major isoflavone C-glycoside isolated from Pueraria lobata, a traditional Chinese medicine widely used for the treatment of alc. intoxication. In order to understand the mode of action of puerarin in the reward pathway of the central nervous system and to study its bioavailability and pharmacokinetics, we developed a synthetic route for the preparation of tritium-labeled puerarin. The key intermediate I (R = TMS, R1 = CH2OH) was obtained by trimethylsilyl protection of all hydroxyl groups followed by selective deprotection. The corresponding aldehyde I (R = TMS, R1 = CH0) was obtained through the subsequent oxidation of the primary alc. Standard NaB[3H]4 reduction and hydrolysis produced the tritium-labeled puerarin I [R = TMS, R1 = CH(3H)OH].

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of tritium-labeled puerarin as potential antidipsotropic agent)

RN 1029605-66-0 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-hydroxy-8-[2,3,4,6-tetrakis-O-(trimethylsily1)-  $\beta$ -D-glucopyranosy1]-3-[4-[(trimethylsily1)oxy]pheny1]- (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
Ь9
      ANSWER 12 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
AN
      2007:962613 CAPLUS
DN
      149:32477
      Synthesis of a novel type of phosphates of puerarin
TΤ
      Chen, Xiao-Lan; Qu, Ling-Bo; Yuan, Jin-Wei; Zhao, Yu-Fen Department of Chemistry, Key Laboratory of Chemical Biology, Zhengzhou University, Zhengzhou, 450052, Peop. Rep. China Journal of the Chinese Chemical Society (Taipei, Taiwan) (2007), 54(3),
ΑU
CS
SO
      583-585
      CODEN: JCCTAC; ISSN: 0009-4536
PΒ
      Chinese Chemical Society
DT
      Journal
LA
      English
OS
      CASREACT 149:32477
      A novel type of phosphated puerarin derivs. were synthesized through a
AB
      simplified Atheron-Todd reaction for the first time. The structure of these compds. were elucidated by IR, ESI-MS and NMR. Moreover, the reason
      the dialkylphophite reagent had different chemselectivities toward
      different hydroxys on the puerarin was discussed.
      913627-26-6P 1010820-83-3P 1031330-85-4P 1031330-87-6P 1031330-89-8P 1031330-93-4P
      1031330-95-6P 1031330-97-8P 1031331-00-6P
      1031331-02-8P
      RL: SPN (Synthetic preparation); PREP (Preparation)
          (synthesis of novel type of phosphates of puerarin)
      913627-26-6 CAPLUS
      4H-1-Benzopyran-4-one, 7-[(diethoxyphosphinyl)oxy]-8-\beta-D-
CN
      glucopyranosyl-3-(4-hydroxyphenyl)- (CA INDEX NAME)
```

## 10/563,471

1010820-83-3 CAPLUS RN

Phosphoric acid,  $8-\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl bis(1-methylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.

1031330-85-4 CAPLUS Phosphoric acid, 4-[7-[(diethoxyphosphinyl)oxy]-8- $\beta$ -D-glucopyranosyl-4-oxo-4H-1-benzopyran-3-yl]phenyl diethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN

1031330-87-6 CAPLUS Phosphoric acid, 8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl dipropyl ester (CA INDEX NAME)

Absolute stereochemistry.

1031330-89-8 CAPLUS

Phosphoric acid, 4-[7-[(dipropoxyphosphinyl)oxy]-8- $\beta$ -D-glucopyranosyl-4-oxo-4H-1-benzopyran-3-yl]phenyl dipropyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN

1031330-93-4 CAPLUS Phosphoric acid, 4-[7-[[bis(1-methylethoxy)phosphinyl]oxy]-8- $\beta$ -D-glucopyranosyl-4-oxo-4H-1-benzopyran-3-yl]phenyl bis(1-methylethyl) ester CN(CA INDEX NAME)

Absolute stereochemistry.

RN 1031330-95-6 CAPLUS

Phosphoric acid, dibutyl 8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl ester (CA INDEX NAME)

Absolute stereochemistry.

1031330-97-8 CAPLUS RN

Phosphoric acid, dibutyl 4-[7-[(dibutoxyphosphinyl)oxy]-8- $\beta$ -D-glucopyranosyl-4-oxo-4H-1-benzopyran-3-yl]phenyl ester (CA INDEX NAME)

Absolute stereochemistry.

Phosphoric acid,  $8-\beta-D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl bis(2-methylpropyl) ester (CA INDEX NAME)$ CN

Absolute stereochemistry.

1031331-02-8 CAPLUS RN

Phosphoric acid,  $4-[7-[[bis(2-methylpropoxy)phosphinyl]oxy]-8-\beta-D-glucopyranosyl-4-oxo-4H-1-benzopyran-3-yl]phenyl bis(2-methylpropyl) ester$ CN (CA INDEX NAME)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 13 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:852415 CAPLUS
- DN 147:480075
- TI Effects of hydroxyethylpuerarin on levels of NO and NOS in rats with ischemia-reperfusion injury
- AU Wang, Ziying; Wei, Xinbing; Sun, Ru; Sun, Xia; Zhang, Xiumei; Zhong, Ying; Zuo, Chunxu
- CS School of Medicine, Shandong University, Jinan, Shandong Province, 250012, Peop. Rep. China
- SO Zhongguo Yaoxue Zazhi (Beijing, China) (2006), 41(2), 112-114 CODEN: ZYZAEU; ISSN: 1001-2494
- PB Zhongguo Yaoxue Zazhishe
- DT Journal
- LA Chinese
- AB The effects of hydroxyethylpuerarin on NO and NOS in rats with focal brain ischemia-reperfusion injury were investigated. Rats were divided into 6 groups randomly, sham-operate group, ischemia-reperfusion group, nimodipine 0.4 mg/kg-1/d-1 group and hydroxyethylpuerarin 30, 60, 120 mg/kg-1/d-1 groups. Rats were prepared with focal brain ischemic injury by middle cerebral artery occlusion (MCAO), and then recovered perfusion by pulling out the suture after 1 h. Rats were treated with medicine at 30 min before and 1, 24, and 36 h after operation. Tissue from the forebrain was homogenized 48 h after reperfusion, and NO and nitric oxide synthase (NOS), including total NOS and inducible nitric oxide synthase (iNOS) were determined NO and NOS levels were significantly increased in the brain tissue of ischemia-reperfusion group compared with sham-operate group. While being compared with ischemia-reperfusion group, NO and NOS levels were significantly decreased in the three hydroxyethylpuerarin-treated groups. Hydroxyethylpuerarin can reduce ischemia-reperfusion injury through decreasing the damages of NO.
- IT 240131-05-9, Hydroxyethylpuerarin
  - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
  - (Biological study); USES (Uses)
    - (effects of hydroxyethylpuerarin on levels of NO and NOS in rats with ischemia-reperfusion injury)
- RN 240131-05-9 CAPLUS
- CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

- L9 ANSWER 14 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:723273 CAPLUS
- DN 147:197605
- TI Studies on chemical constituents of Patrinia villosa
- AU Peng, Jinyong; Fan, Guorong; Wu, Yutian
- CS College of Pharmacy, Second Military Medical University, Shanghai, 200433, Peop. Rep. China
- SO Zhongguo Zhongyao Zazhi (2006), 31(2), 128-130 CODEN: ZZZAE3; ISSN: 1001-5302
- PB Zhongguo Zhongyao Zazhishe
- DT Journal

LA Chinese

AB The objective of this study is to investigate the chemical constituents of Patrinia villosa. The chemical constituents were isolated by silica gel column chromatog. and semi-preparative high-performance liquid chromatog., and identified by physicochem. properties and spectral anal. (MS, 1H- NMR and 13C-NMR). Seven compds. were isolated from Et acetate and n-butanol extract and identified as: 5-hydroxyl-7, 3',4'-trimethoxy flavone (I), 5-hydroxyl-7, 4'-dimethoxy flavone (II), luteolin (III), quercetin (IV), isoorientin (V), isovitexin (VI) and 8-C glucosylprunetin (VII). Compds. I, II, III, V, VI, and VII were obtained from the plant of genus Patrinia for the first time, compound IV was separated from P. villosa for the first time.

IT 52448-12-1P

RL: PUR (Purification or recovery); PREP (Preparation) (studies on chemical constituents of Patrinia villosa)

RN 52448-12-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-5-hydroxy-3-(4hydroxyphenyl)-7-methoxy- (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 15 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:723016 CAPLUS

DN 147:181221

TI Protective effects of hydroxyethylpuerarin against brain astrocytes injury induced by hydrogen peroxide

AU Zhang, Bin; Wei, Xinbing; Liu, Huiqing; Wang, Lixiang; Sun, Ru; Zhang, Xiumei

CS Institute of Pharmacology, School of Medicine, Shandong University, Jinan, 250012, Peop. Rep. China

SO Yaoxue Xuebao (2006), 41(2), 171-174 CODEN: YHHPAL; ISSN: 0513-4870

PB Yaoxue Xuebao Bianjibu

DT Journal

LA Chinese

The objective is to study the protective effects of hydroxyethylpuerarin against the injury of astrocytes induced by hydrogen peroxide(H2O2). Expts. were performed with cells from passage 4. Plasma membrane integrity was measured by lactate dehydrogenase(LDH) release. The occurrence of apoptosis was measured by flow cytometry. The glutamate uptake of astrocytes was studied with [3H]-glutamate incorporation. Intracellular superoxide dismutase(SOD) activity and malondialdehydelevel were assessed by automatic biochem. analyzer. Compared with H2O2 injured group, the occurrence of apoptosis, levels of LDH release and intracellular MDA of astrocytes reduced in hydroxyethylpuerarin pre-treated groups, but the glutamate up take and intracellular SOD activity of astrocytes increased. Hydroxyethylpuerarin could reduce the occurrence of apoptosis and improve neurotrophic function of astrocytes, which may be related with its antioxidant effects during oxidative stress.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(protective effects of hydroxyethylpuerarin against brain astrocytes injury induced by hydrogen peroxide)

240131-05-9 CAPLUS RN

4H-1-Benzopyran-4-one,  $8-\beta$ -D-qlucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 16 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2007:591008 CAPLUS Ь9

AN

147:95471 DN

TΙ Method for preparation of lactyl puerarin derivatives

IN

PA

Huo, Danqun; Hou, Changjun; Shu, Mao Chongqing University, Peop. Rep. China Faming Zhuanli Shenqing Gongkai Shuomingshu, 13pp. SO

CODEN: CNXXEV

DT Patent

LΑ Chinese

FAN.CNT 1

GΙ

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1970558	A	20070530	CN 2006-10095262	20061207
PRAI	CN 2006-10095262		20061207		
OS	CASREACT 147:95471:	MARPAT	147:95471		

The claimed lactyl puerarin derivs. have a general formula I (R1,R2,R3,R4,R5,R6=H or lactyl, and at least one lactyl exist). Claimed lactyl puerarin derivs. were prepared from lactic acid and thionyl chloride to obtain lactyl chloride, then esterification with puerarin in a basic solvent (such as anhydrous pyridine, tetrahydropyridine, triethylamine and DMF) to provide the products. The method is environment-friendly, and has the advantages of simple operation, high yield (greater than 55%), simple product purification, recoverable solvents, and low manufacturing cost.

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of lactyl puerarin derivs. via esterification of puerarin with lactyl chloride)

RN 905916-27-0 CAPLUS

4H-1-Benzopyran-4-one,  $8-\beta$ -D-qlucopyranosyl-7-hydroxy-3-[4-(2-hydroxy-1-oxopropoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 17 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN T. 0

AN 2007:447975 CAPLUS

147:87267 DN

Effects of acetylpuerarin on hippocampal neurons and intracellular free calcium subjected to oxygen-glucose deprivation/reperfusion in primary

Liu, Rui; Wei, Xin-Bing; Zhang, Xiu-Mei ΑU

Department of Pharmacology, School of Medicine, Shandong University, CS Shandong, 250012, Peop. Rep. China

so Brain Research (2007), 1147, 95-104 CODEN: BRREAP; ISSN: 0006-8993

PΒ Elsevier Ltd.

DT Journal

English LA

This study was undertaken to find out the effects of acetylpuerarin on hippocampal neurons and intracellular free calcium in primary culture subjected to oxygen-glucose deprivation/reperfusion. According to different reperfusion time (1 h, 6 h, 12 h, 24 h), three concns. (1.6  $\mu mol$  1-1, 0.4  $\mu mol$  1-1, 0.1  $\mu mol$  1-1) of acetylpuerarin, and MK-801 (10  $\mu$ mol 1-1), a pos. control drug, neurons were randomly divided into 21 groups. Each group was observed by inverted phase contrast microscope; neuron viability was measured by the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT); intracellular Ca2+ was observed by Fura-2/AM ester through fluorospectrophotometer. The injured neurons were protected and degeneration and necrosis were alleviated in treatment groups of acetylpuerarin and MK-801. Acetylpuerarin increased the neuron viability at high, middle and low concns. Fluorescence detection results showed that the calcium concentration in the group treated with acetylpuerarin and MK-801 was lowered in each reperfusion time. Our results demonstrated that acetylpuerarin could protect the hippocampal neurons from ischemia-reperfusion injury in rats by alleviating the morphol. damage, increasing neuron viability and decreasing calcium concentration in neuron. 2889-07-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of acetylpuerarin on hippocampal neurons and intracellular free calcium subjected to oxygen-glucose deprivation/reperfusion in primary culture)

RN 2889-07-8 CAPLUS

4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-4)tetra-O-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-3-[4-( $\beta$ -D-glucopyranosyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

```
ANSWER 18 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2007:416242 CAPLUS
T. 9
AN
DN
       146:475689
      Method for manufacturing composition for treating cardiovascular and
TΙ
      cerebrovascular diseases
      Chen, Dihua; Du, Lijun; Si, Jianyong; Chang, Qi; You, Baocheng; Ma, Nan; Lu, Zhenmin; Pan, Xueqing; Yang, Lin; Sun, Baohua
IN
      Institute of Medicinal Plant Development, Chinese Academy of Medical
PA
      Sciences, Peop. Rep. China; Anhui Gujing Group Jiufang Pharmaceutical Co.,
      Faming Zhuanli Shenqing Gongkai Shuomingshu, 22pp.
SO
      CODEN: CNXXEV
DT
      Patent
LΑ
      Chinese
FAN.CNT 1
      PATENT NO.
                                  KIND
                                            DATE
                                                            APPLICATION NO.
                                                                                             DATE
      CN 1943584
                                   Α
                                            20070411
                                                             CN 2006-10113893
                                                                                             20061020
PRAI CN 2006-10113893
                                           20061020
      The title composition is composed of (by weight parts) formononetin-7-0-glucoside 4.5-5.5, daidzin 6.7-8.2, 3'-methoxyl puerarin 4.5-5.5, puerarin 44-54,
      glucoside B of Radix Puerariae 1.8-2.2,
      daidzein-8-C-apiosyl-(1-6)-glucoside 17-21, puerarin xyloside 2.7-3.3, daidzein-7,4'-diglucoside 0.9-1.3, 3'-hydroxy puerarin 4.5-5.5,
      puerarin-4'-0-glucoside 3.3.7, quercetin-4'-0-glucoside 0.4-0.5, 4'-methoxyl genistin 0.9-1.0, and glucoside C of Radix Puerariae 0.9-1.3. The composition can be used for inhibiting platelet aggregation, lowering blood
      viscosity, activating fibrinolysin, and inhibiting thrombosis.
       117047-08-2P
      RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
       (Uses)
           (method for manufacturing composition for treating cardiovascular and
           cerebrovascular diseases)
```

Absolute stereochemistry.

117047-08-2 CAPLUS

```
L9 ANSWER 19 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
```

AN 2007:416144 CAPLUS

DN 146:448275

TI Puerarin derivatives and its medicinal application

IN Feng, Zhiqiang; Guo, Zongru; Chu, Fengming; Sun, Piaoyang; Zhou, Yunshu; Yuan, Kaihong

PA Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China; Jiangsu Hengrui Medicine Co., Ltd.

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 24pp. CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1944448	A	20070411	CN 2006-10000814	20060111
PRAT	CN 2005-10000423	Δ	20050111		

AB The invention discloses puerarin derivs. represented in a general formula, its preparation method, medicinal combination containing one or more of such compds., and application of such compds. in preparing drugs related to heart and brain circulation diseases, as well as retinal arteriovenous occlusion, sudden deafness and other diseases and improving memory, and lowering blood sugar.

IT 934696-09-0P 934696-10-3P 934696-11-4P 934696-12-5P 934696-13-6P 934696-15-8P 934696-17-0P 934696-20-5P 934696-21-6P 934696-25-0P 934696-26-1P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(puerarin derivs. and its medicinal application)

RN 934696-09-0 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 8-β-D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl ester (CA INDEX NAME)

934696-10-3 CAPLUS RN

4H-1-Benzopyran-4-one, 7-(acetyloxy)-8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)- (CA INDEX NAME)  $_{\rm CN}$ 

Absolute stereochemistry.

934696-11-4 CAPLUS RN

Propanoic acid, 2,2-dimethyl-,  $4-[7-(2,2-dimethyl-1-oxopropoxy)-8-\beta-D-glucopyranosyl-4-oxo-4H-1-benzopyran-3-yl]phenyl ester (CA INDEX NAME)$ CN

Absolute stereochemistry.

934696-12-5 CAPLUS RN

Propanoic acid, 2,2-dimethyl-, 4-[7-(2,2-dimethyl-1-oxopropoxy)-8-[6-0-(2,2-dimethyl-1-oxopropyl)- $\beta$ -D-glucopyranosyl]-4-oxo-4H-1-benzopyran-3-yl]phenyl ester (CA INDEX NAME) CN

## 10/563,471

RN 934696-13-6 CAPLUS

4H-1-Benzopyran-4-one, 7-(benzoyloxy)-3-[4-(benzoyloxy)phenyl]-8- $\beta$ -D-glucopyranosyl- (CA INDEX NAME)  $_{\rm CN}$ 

Absolute stereochemistry.

934696-15-8 CAPLUS RN

4H-1-Benzopyran-4-one, 3-[4-(acetyloxy)phenyl]-7-hydroxy-8-(2,3,4-tri-0-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME) CN

Absolute stereochemistry.

934696-17-0 CAPLUS RN

4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,4-di-0-CN $acetyl-\beta-D-glucopyranosyl)-$  (CA INDEX NAME)

RN934696-20-5 CAPLUS

Propanoic acid, 2,2-dimethyl-, [[8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]methyl ester (CA INDEX CN

Absolute stereochemistry.

934696-21-6 CAPLUS Propanoic acid, 2,2-dimethyl-, [4-[7-[(2,2-dimethyl-1-oxopropoxy)methoxy]-8- $\beta$ -D-glucopyranosyl-4-oxo-4H-1-benzopyran-3-yl]phenoxy]methyl ester RNCN(CA INDEX NAME)

Absolute stereochemistry.

934696-25-0 CAPLUS RN

4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)-3-(dimethylamino)phenyl]-8-(2,3,4,6-tetra-0-acetyl- $\beta$ -D-glucopyranosyl)-(CA INDEX NAME)

Absolute stereochemistry.

RN 934696-26-1 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 2-(dimethylamino)-4-[7-(2,2-dimethyl-1oxopropoxy)-8-β-D-glucopyranosyl-4-oxo-4H-1-benzopyran-3-yl]phenyl
ester (CA INDEX NAME)

- L9 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:211423 CAPLUS
- DN 146:434929
- TI Flavonoids Possess Neuroprotective Effects on Cultured Pheochromocytoma PC12 Cells: A Comparison of Different Flavonoids in Activating Estrogenic Effect and in Preventing  $\beta$ -Amyloid-Induced Cell Death
- AU Zhu, Judy T. T.; Choi, Roy C. Y.; Chu, Glanice K. Y.; Cheung, Anna W. H.; Gao, Qiu T.; Li, Jun; Jiang, Zhi Y.; Dong, Tina T. X.; Tsim, Karl W. K.
- CS Departments of Biology and Center for Chinese Medicine, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, Peop. Rep. China
- SO Journal of Agricultural and Food Chemistry (2007), 55(6), 2438-2445 CODEN: JAFCAU; ISSN: 0021-8561
- PB American Chemical Society
- DT Journal
- LA English
- AB Despite the classical hormonal effect, estrogen possesses a neuroprotective effect in the brain, which has led many to search for novel treatments for neurodegenerative diseases. Flavonoids, a group of compds. mainly derived from vegetables, share a resemblance, chemical, to estrogen, and indeed, some have been used as estrogen substitutes. To search for potential therapeutic agents against neurodegenerative diseases, different subclasses of flavonoids were analyzed and compared with estrogen. First, the estrogenic activities of these flavonoids were determined by activating the estrogen-responsive elements in cultured MCF-7

breast cancer cells. Second, the neuroprotective effects of flavonoids were revealed by measuring its inhibition effects on the formation of reactive oxygen species, the aggregation of  $\beta$ -amyloid, and the induction of cell death by  $\beta$ -amyloid in cultured neuronal PC12 cells. Among these flavonoids, baicalein, scutellarin, hibifolin, and quercetin-3'-glucoside possessed the strongest effect in neuroprotection; however, the neuroprotective activity did not directly correlate with the estrogenic activity of the flavonoids. Identification of these flavonoids could be very useful in finding potential drugs, or food supplements, for treating Alzheimer's disease.

IT 69655-50-1 905916-24-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells and comparison of different flavonoids in activating estrogenic effect and in preventing  $\beta-$ amyloid-induced cell death)

RN 69655-50-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-methoxy-3-(4-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 905916-24-7 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8- $\beta$ -D-glucopyranosyl- (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 21 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:165340 CAPLUS
- DN 146:400737
- TI Puerarin and Conjugate Bases as Radical Scavengers and Antioxidants: Molecular Mechanism and Synergism with  $\beta\text{--}\text{Carotene}$

- ΑIJ Han, Rui-Min; Tian, Yu-Xi; Becker, Eleonora Miquel; Andersen, Mogens L.; Zhang, Jian-Ping; Skibsted, Leif H.
- CS Department of Chemistry, Renmin University of China, Beijing, 100872, Peop. Rep. China
- SO Journal of Agricultural and Food Chemistry (2007), 55(6), 2384-2391 CODEN: JAFCAU; ISSN: 0021-8561
- PB American Chemical Society
- DT Journal
- English LΑ
- The 4'-hydroxyl group of puerarin, a C-glycoside of the isoflavonoid daidzein, was shown, using 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) radical cation and stopped-flow spectroscopy and by comparison with the 7-propylpuerarin (A ring derivative) and 4'-propylpuerarin (B ring derivative), to be a more efficient radical scavenger as compared to the 7-hydroxyl group by a factor of 2, a difference increasing upon deprotonation. The difference in radical scavenging agreed with the oxidation potentials (cyclic voltammetry in acetonitrile, 0.1 M Bu4NBF4 at 25 °C):  $E/mV = 862 \pm 3$  for puerarin, 905  $\pm$  10 for 7-propylpuerarin, and  $1064 \pm 2$  for 4'-propylpuerarin relative to ferrocene/ferricenium. In aqueous solution, the reduction potential was shown to decrease for increasing pH, and deprotonation of the 4'-hydroxyl group increased radical scavenging more than deprotonation of the 7-hydroxyl group. The 7-hydroxyl was found to be more acidic (pKa1 =  $7.20\pm0.01$  in puerarin and pKa =  $7.23\pm0.01$  in 4'-propylpuerarin) than the 4'-hydroxyl group (pKa2 =  $9.84 \pm 0.08$  in puerarin and pKa =  $9.51 \pm$ 0.02 in 7-propylpuerarin); aqueous solution, ionic strength of 0.1, and 25 °C. In phosphatidyl choline liposome of pH 7.4, puerarin and  $\beta\text{--carotene}$  each showed a modest antioxidant activity measured as prolongation of the lag phase for formation of conjugate dienes and using the water-soluble radical initiator APPH with effects of puerarin and  $\beta\text{--}carotene$  being additive. For the lipophilic initiator AMVN, the antioxidative effect decreased for puerarin and increased for  $\beta\text{--carotene}$  as compared to APPH and showed a clear synergism. A regeneration of  $\beta$ -carotene, effective in the liposome lipid phase as antioxidant, from the cation radical by deprotonated forms of puerarin was demonstrated in 9:1 chloroform/methanol using laser flash photolysis with k2 = 2.7 + 104 L mol-1 s-1 for the bimol. process between the cation radical and the puerarin dianion.
- 623900-91-4 933984-62-4 933984-63-5
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (puerarin and conjugate bases as radical scavengers and antioxidants as to mol. mechanism and synergism with  $\beta$ -carotene)
- RN 623900-91-4 CAPLUS
- 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-propoxy-3-(4propoxyphenyl) - (CA INDEX NAME)

Absolute stereochemistry.

 $\texttt{4H-1-Benzopyran-4-one, 8-\beta-D-glucopyranosyl-3-(4-hydroxyphenyl)-7-} \\$ CN propoxy- (CA INDEX NAME)

RN 933984-63-5 CAPLUS

4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-hydroxy-3-(4-CNpropoxyphenyl) - (CA INDEX NAME)

THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 31 ALL CITATIONS AVAILABLE IN THE RE FORMAT

- ANSWER 22 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:124524 CAPLUS
- 147:207675 DN
- ΤI Chemical constituents from Pueraria lobata
- ΑU
- Si, Jian-yong; Chang, Qi; Shen, Lian-gang; Chen, Di-hua Institute of Medicinal Plant Development, Chinese Academy of Medical CS Sciences and Peking Union Medical College, Beijing, 100094, Peop. Rep. China
- SO Journal of Chinese Pharmaceutical Sciences (2006), 15(4), 248-250 CODEN: JCHSE4; ISSN: 1003-1057
- PB Journal of Chinese Pharmaceutical Sciences
- DT Journal
- LAEnglish
- AΒ The chemical isolation of fourteen compds. from Pueraria lobata and their structures are presented. Such compds. include daidzein, ononin, daidzin, 3'-methoxy puerarin, puerarin, pueroside B, daidzein-8-C-apiosyl-(1-6)-glucoside, 3'-hydroxy-puerarin, puerarinxyloside, daidzein-7, 4'0-glucoside, puerarin-4'-0-glucoside, mirificin-4'-0-glucoside, sissotorin, and pueroside C.
- 117047-08-2P 168035-01-6P, Mirificin-4-O-glucoside RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation) (chemical constituents from Pueraria lobata)
- 117047-08-2 CAPLUS
- 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-3-[4-( $\beta$ -Dglucopyranosyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 168035-01-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 8-(6-O-D-apio- $\beta$ -D-furanosyl- $\beta$ -D-glucopyranosyl)-3-[4-( $\beta$ -D-glucopyranosyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:1202181 CAPLUS

DN 146:32821

TI Medicinal composite containing borneol and musk for curing coma, cardiovascular disease, cerebrovascular disease, senile dementia and diabetes

IN Lin, Yanhe

PA Shenzhen Biovalley Technologies Co., Ltd., Peop. Rep. China

SO Faming Zhuanli Shenging Gongkai Shuomingshu, 19pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

111111 0111 1						
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	CN 1857447	A	20061108	CN 2006-10065847	20060327	
PRAI	CN 2006-10065847		20060327			

AB The medicinal composite comprises active component 10-90 wt% and adjuvant 90-10 wt%. The active component comprises a) borneol; b)musk or its extract; c) Paeonia albiflora or its extract; d) extract of Salvia miltiorrhiza, or gingko biloba, or safflower, puerarin, rhizoma chuanxiong and panax ginseng. The medicinal composite containing borneol and musk is used to cure coma, cardiovascular disease, cerebrovascular disease, senile dementia and diabetes.

IT 24562-39-8, Puerarin diacetate

RL: NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(preparation of medicinal composite containing borneol and musk for curing coma,

cardiovascular disease, cerebrovascular disease, senile dementia and diabetes)

RN 24562-39-8 CAPLUS

CN 4H-1-Benzopyran-4-one, 8-(6-0-acetyl- $\beta$ -D-glucopyranosyl)-3-[4-(acetyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

- L9 ANSWER 24 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2006:1202175 CAPLUS
- DN 146:32925
- TI Medicinal composite containing musk for curing coma, cardiovascular disease, cerebrovascular disease, senile dementia and diabetes
- IN Lin. Yanhe
- PA Shenzhen Biovalley Technologies Co., Ltd., Peop. Rep. China
- SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 17pp. CODEN: CNXXEV
- DT Patent
- LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1857446	A	20061108	CN 2006-10065846	20060327
PRAI	CN 2006-10065846		20060327		

AB The medicinal composite comprises active component 10-90 wt% and adjuvant 90-10 wt%. The active component comprises a) musk or its extract; b) Paeonia albiflora or its extract; c) extract of Salvia miltiorrhiza, or gingko biloba, or safflower, puerarin, rhizoma chuanxiong and panax ginseng. The medicinal composite containing borneol and musk is used to cure coma, cardiovascular disease, cerebrovascular disease, senile dementia and diabetes.

IT 24562-39-8, Puerarin diacetate

RL: NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(preparation of medicinal composite containing musk for curing coma, cardiovascular disease, cerebrovascular disease, senile dementia and diabetes)

RN 24562-39-8 CAPLUS

N 4H-1-Benzopyran-4-one, 8-(6-0-acetyl-β-D-glucopyranosyl)-3-[4-(acetyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

```
ANSWER 25 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
T. 9
AN
     2006:1038255 CAPLUS
DN
     147:31285
     Synthesis and characterization of puerarin derivatives and the mechanism
TΙ
     of derivation reaction
ΑU
     Han, Rui-Min; Tian, Yu-Xi; Wang, Peng; Xiang, Jun-Feng; Ai, Xi-Cheng;
     Zhang, Jian-Ping
     State Key Lab. Structural Chem. of Unstable and Stable Species, Chinese
CS
     Acad. Sci., Beijing, 100080, Peop. Rep. China
SO
     Gaodeng Xuexiao Huaxue Xuebao (2006), 27(9), 1716-1720
     CODEN: KTHPDM; ISSN: 0251-0790
     Gaodeng Jiaoyu Chubanshe
PB
DT
     Journal
LΑ
     Chinese
     CASREACT 147:31285
OS
     7,4'-Dipropylpuerarin [i.e., 8-(\beta-D-glucopyranosyl)-7-propoxy-3-(4-
AB
     propoxyphenyl)-4H-1-benzopyran-4-one] (I), 7-(propyl)puerarin (II) and
     4'-(propyl)puerarin (III) were synthesized and characterized by using 1H
     NMR, NOESY and HRMS. Among the derivs., II is a new-type of substituted
     compound of puerarin. 1H NMR spectroscopic anal. of aromatic protons combined
     with theor. anal. of mol. structures proved the existence of two
     rotational isomers at 300 K, as well as a rapid interconversion equilibrium at
     330 K for both compds. I and II. However, only one conformer exists for
     compound III and puerarin containing a 7-phenolic hydroxy group instead of Pr in
     the A-ring as the case of compds. I and II. Based on UV-Visible
     absorption data of neutral and basic solns., and on the d. function
     calcns., the 7-phenolic hydroxy group in the A-ring was found to be more
     acidic than the 4'-phenolic hydroxyl group in B-ring. The mechanism of derivation reaction and the structure-reactivity relationship of puerarin
     as an antioxidant were further discussed.
     623900-91-4P, 7,4'-Dipropylpuerarin 933984-62-4P,
     7-Propylpuerarin 933984-63-5P, 4'-Propylpuerarin
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
         (preparation of (propyl) puerarin derivs., study of properties of their
        conformers and rotamers and study of their antioxidant
        structure-activity relationship)
     623900-91-4 CAPLUS
     4H-1-Benzopyran-4-one, 8-\beta-D-glucopyranosyl-7-propoxy-3-(4-propoxyphenyl)- (CA INDEX NAME)
```

Absolute stereochemistry.

933984-63-5 CAPLUS RN

4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-(4-propoxyphenyl)- (CA INDEX NAME) CN

- ANSWER 26 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2006:936445 CAPLUS L9
- AN
- DN 145:342398
- Application of hexaacetylpuerarin as medicine for treating ischemic ΤI cerebrovascular diseases
- Zuo, Chunxu; Zhang, Youmei; Zhong, Ying; Li, Xuemei; Hou, Li; Liu, Jikai;  ${\tt IN}$

Lin, Zhonglian; Chen, Jianqiang; Li, Anguo; Yan, Qinbin; He, Hongping; Yang, Min

PA Shanxi Zhenping Pharmaceutical Factory, Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 15pp. CODEN: CNXXEV

DT Patent

Chinese LA

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
PI CN 1823801	A	20060830	CN 2005-10042516	20050225		
DRAT CN 2005-10042516		20050225				

Hexaacetylpuerarin is prepared by extracting Pueraria lobata, dissolving the extract in acetic anhydride, and acetylating to obtain a bioactive puerarin derivative (hexaacetylpuerarin). Hexaacetylpuerarin can be used in medicine, especially oral agent, for treating ischemic cerebrovascular diseases.

2889-07-8P, Puerarin, hexaacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(application of hexaacetylpuerarin as medicine for treating ischemic cerebrovascular diseases)

2889-07-8 CAPLUS RN

4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-4)CN tetra-O-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 27 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:907251 CAPLUS

145:342220 DN

Medical composition containing borneol for treating cardio-cerebral ΤТ vascular diseases and diabetes

ΤN Lin. Yanhe

Shenzhen Biovalley Technologies Co., Ltd., Peop. Rep. China PA

so Faming Zhuanli Shenqing Gongkai Shuomingshu, 30pp.

CODEN: CNXXEV

DT Patent

T.A Chinese FAN CNT

EAIN.		ENT NO.	KIND	DATE	APPLICATION NO.	DATE
	FAI		KIND	DAIL	AFFIICATION NO.	DAIL
PI	CN	1823922	 A	20060830	CN 2005-10132563	20051226
	CN	100391489	C	20080604		
PRAI	CN	2005-10132563		20051226		

PRAI CN 2005-10132563 The title medical composition is composed of active constituent 10-90 and pharmaceutical adjuvant 90-10%, wherein active constituent comprises borneol 1-15, Paeonia root powder or active ingredient thereof 5-85 and/or Salvia miltiorrhiza extract, Erigeron breviscapus or its extract, Carthamus tinctorius extract, isoflavonoid extract, ginkgo extract, Ligusticum chuanxiong extract and/or ginseng extract 15-200 part. The medical composition can be prepared into tablet, soft capsule, dripping pill, oral disintegrating tablet, slow-release tablet, freeze-dried powder for treating coma,

cardio-cerebral vascular diseases and diabetes.

303114-83-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(herbal composition containing borneol for treating cardio- and cerebro-vascular diseases and diabetes)

303114-83-2 CAPLUS RN

4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-7-( $\beta$ -D-xylopyranosyloxy)- (CA INDEX NAME) CN

Absolute stereochemistry.

ANSWER 28 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2006:695558 CAPLUS T.9

AN

DN 145:249448

TΤ

Preparation of puerarin derivatives as antiischemics Huo, Danqun; Shi, Kaiyun; Hou, Changjun; Shu, Mao IN

PA

Chongqing University, Peop. Rep. China Faming Zhuanli Shenqing Gongkai Shuomingshu, 9 pp.

CODEN: CNXXEV

DT Patent

 $\mathbb{L} \mathsf{A}$ Chinese

FAN.CNT 1

T. PATA .	⊃1/ T T					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	CN 1800196	A	20060712	CN 2006-10054014	20060110	
PRAI	CN 2006-10054014		20060110			
OS	CASREACT 145:249448;	MARPAT	r 145:249448			
GI						

The title derivs. I [R1, R2 = H, alkyl, linear or branched alkanoyl or aroyl, or metal (Na, K, Mg, Ca, or Zn) ion with the proviso that R1 and R2 are not H at the same time; and 1-site of D-glucosyl is connected with 8-site of isoflavone by  $\beta$ -configuration] are prepared by butylating puerarin with di-Bu sulfate, di-Bu carbonate, or Bu halide in ketone or alc.; or acylating puerarin with acyl halide in water, haloalkane, ketone or alc. under neutral or weakly basic condition; or reacting puerarin with

Absolute stereochemistry.

RN 905916-24-7 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8- $\beta$ -D-glucopyranosyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 905916-27-0 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-(2-hydroxy-1-oxopropoxy)phenyl]- (CA INDEX NAME)

905916-32-7 CAPLUS

Benzoic acid, 2-(acetyloxy)-,  $4-[8-\beta-D-glucopyranosyl-7-hydroxy-4-oxo-property]$ 4H-1-benzopyran-3-yl]phenyl ester (9CI) (CA INDEX NAME)

- ANSWER 29 OF 79 CAPLUS COPYRIGHT 2009 ACS on SIN T. 9
- AN 2006:525663 CAPLUS
- DN 145:348396
- Protective effects of hydroxyethylpuerarin on cultured bovine cerebral TI microvascular endothelial cells damaged by hydrogen peroxide
- ΑU Guang, Hongmei; Zhang, Xiumei; Li, Yingquan; Wei, Xinbing; Wang, Ziying; Liu, Huiging
- Department of Pharmacology, School of Medicine, Shandong University, Jinan, 250012, Peop. Rep. China
  Yaoxue Xuebao (2005), 40(3), 220-224
  CODEN: YHHPAL; ISSN: 0513-4870 CS
- SO
- Yaoxue Xuebao Bianjibu PΒ
- DT Journal
- LA English
- The damages induced by H2O2 in cultured bovine cerebral microvascular endothelial cells (BCMEC) were observed and the protective effects of hydroxyethylpuerarin on H2O2-injured BCMEC were evaluated. BCMECs were cultured and transferred into modified Eagle medium (MEM). The viability of cells was detected by MTT assay. Cell injury was determined by lactate dehydrogenase (LDH) activity in the extracellular medium. Flow cytometry was used to observe the occurrence of apoptosis. Morphol. changes of cells were visualized under phase contrast and electron microscopes. H2O2 (200  $\mu$ M, for 4 h) inhibited the viability of cultured BCMEC and stimulated LDH release. H202 (100  $\mu\text{M}\text{,}$  for 4 h) induced the occurrence of apoptosis. Hydroxyethylpuerarin increased the survival rate and decreased the activity of LDH of BCMEC damaged by H2O2.

Hydroxyethylpuerarin also protected BCMEC against apoptosis induced by H2O2. H2O2 induces BCMEC injury either by apoptosis or through necrosis, hydroxyethylpuerarin protects BCMEC against H2O2-induced injury in a concentration-dependent manner, and its antioxidant effects might be involved as the mechanism protection.

IT 240131-05-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(protective effects of hydroxyethylpuerarin on cerebral microvascular endothelial cells)

RN 240131-05-9 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 30 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2006:500363 CAPLUS

DN 146:198334

- TI Effect of acetylpuerarin on NO level and NOS activity in brain tissue and serum of focal cerebral ischemia reperfusion injury rats
- AU Li, Xuemei; Wei, Xinbing; Zhang, Xiumei; Hou, Li; Zhong, Ying; Zuo, Chunxu
- CS School of Medicine, Shandong University, Jinan, Shandong Province, 250012, Peop. Rep. China
- SO Zhongguo Yaoxue Zazhi (Beijing, China) (2005), 40(11), 829-832 CODEN: ZYZAEU; ISSN: 1001-2494
- PB Zhongguo Yaoxue Zazhishe
- DT Journal
- LA Chinese
- The neuroprotective effect of acetylpuerarin (compound N-2211) and puerarin on focal cerebral ischemia-reperfusion injury was studied. The nitric oxide (NO) level and nitric oxide synthase (NOS) activity in brain tissue and serum were measured in the rats with reversible middle cerebral artery occlusion (MCAO) without craniectomy. The levels of NO and NOS in brain homogenate increased significantly in ischemia-reperfusion group, compared with sham group, and there was the same change happened for the level of NO in serum (P<0.01). NO and NOS levels in brain tissue and NO in serum decreased in acetylpuerarin-treated groups and puerarin-treated group, compared with ischemia-reperfusion rats (P<0.05). At the same time, the number of living pyramidal cells in CA1 region of hippocampus increased significantly in acetylpuerarin-treated rats and puerarin-treated rats, compared with ischemia-reperfusion rats. The results suggested that the effect of acetylpuerarin and puerarin on decreasing NO production played a role on the amelioration of focal brain ischemia-reperfusion injury.

  II 24562-39-8

IT 24562-39-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(effect of acetylpuerarin on NO and NOS in brain and serum of focal cerebral ischemia reperfusion injury rats)

RN 24562-39-8 CAPLUS

CN 4H-1-Benzopyran-4-one, 8-(6-0-acetyl- $\beta$ -D-glucopyranosyl)-3-[4-(acetyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 31 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2006:478988 CAPLUS L9

AN

DN145:145938

ΤΙ Total synthesis of two isoflavone C-qlycosides: Genistein and orobol 8-C-β-D-glucopyranosides

ΑIJ

Sato, Shingo; Hiroe, Kaoru; Kumazawa, Toshihiro; Onodera, Jun-ichi Department of Chemistry and Chemical Engineering, Faculty of Engineering, CS Yamagata University, Yonezawa-shi, Yamagata, 992-8510, Japan Carbohydrate Research (2006), 341(9), 1091-1095 CODEN: CRBRAT; ISSN: 0008-6215

SO

PB Elsevier B.V.

DT Journal

LΑ English

CASREACT 145:145938 OS

GΤ

Genistein and orobol 8-C- $\beta$ -D-glucopyranosides I (R1 = H, R2 = OH; R1 = OH, R2 = OH) were synthesized for the first time in overall yields of 39% and 41% from 2,4-di-O-benzylphloroacetophenone (II). Chalcone glycosides were synthesized via aldol condensation of the benzyl-protected C-glycosylphloroacetophenone, a key intermediate, which was synthesized by a C-glycosylation method involving the O-C glycoside rearrangement of II in 96% yield. Isoflavone glycosides were formed by the formation of acetals by oxidative rearrangement of the protected chalcones using Tl(NO3)3, followed by acid-catalyzed cyclization. Then, debenzylation by hydrogenolysis gave the title compds. 898550-59-9P 898550-60-2P 898550-61-3P

898550-62-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of genistein and orobol 8-C- $\beta$ -D-glucopyranosides via C-glycosylation, aldol condensation, oxidative rearrangement,

acid-catalyzed cyclization and debenzylation/hydrogenolysis from dibenzylphloroacetophenone)

898550-59-9 CAPLUS RN

4H-1-Benzopyran-4-one, 5,7-bis(phenylmethoxy)-3-[4-(phenylmethoxy)phenyl]-8-[2,3,4,6-tetrakis-0-(phenylmethyl)- $\beta$ -D-glucopyranosyl]- (CA INDEX CN

Absolute stereochemistry. Rotation (-).

RN898550-60-2 CAPLUS

4H-1-Benzopyran-4-one, 5-hydroxy-7-(phenylmethoxy)-3-[4-(phenylmethoxy)phenyl]-8-[2,3,4,6-tetrakis-0-(phenylmethyl)- $\beta$ -D-glucopyranosyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 898550-61-3 CAPLUS

4H-1-Benzopyran-4-one, 3-[3,4-bis(phenylmethoxy)phenyl]-5,7-bis(phenylmethoxy)-8-[2,3,4,6-tetrakis-0-(phenylmethyl)- $\beta$ -D-glucopyranosyl]- (CA INDEX NAME) CN

Absolute stereochemistry. Rotation (-).

898550-62-4 CAPLUS RN

4H-1-Benzopyran-4-one, 3-[3,4-bis(phenylmethoxy)phenyl]-5-hydroxy-7-(phenylmethoxy)-8-[2,3,4,6-tetrakis-0-(phenylmethyl)- $\beta$ -D-glucopyranosyl]- (CA INDEX NAME) CN

Absolute stereochemistry. Rotation (-).

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT RE.CNT 29

```
ANSWER 32 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2006:365355 CAPLUS
L9
```

ΑN

DN 144:381954

Synthesis of acetylated puerarin derivatives for improved bioavailability TΙ

Chan, Albert Sun-Chi; Chen, Shi Lin; Li, Yueming; Yang, Dajian ΙN

PA

Hong Kong
U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO SO

 $\mathsf{DT}$ Patent

LA English

FAN.CNT

PATENT				KIN	D	DATE								Di		
				A1		2006	0420							2		
CN 1763	3030			A 20060426				CN 2004-10096209					20041125			
WO 2006	0424	54		A1		20060427		1	WO 2005-CN1676					20051012		
W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KP,	KR,	KZ,
	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,
	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,
	SK,	SL,	SM,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,
	YU,	ZA,	ZM,	ZW												
RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,
	IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,
	US 2006 CN 1763 WO 2006 W:	PATENT NO.  US 20060084 CN 1763030 WO 20060424 W: AE, CN, GE, LC, NA, SK, YU, RW: AT,	PATENT NO.  US 20060084615 CN 1763030 WO 2006042454 W: AE, AG, CN, CO, GE, GH, LC, LK, NA, NG, SK, SL, YU, ZA, RW: AT, BE,	PATENT NO.  US 20060084615 CN 1763030 WO 2006042454 W: AE, AG, AL, CN, CO, CR, GE, GH, GM, LC, LK, LR, NA, NG, NI, SK, SL, SM, YU, ZA, ZM, RW: AT, BE, BG,	PATENT NO. KIN  US 20060084615 A1 CN 1763030 A WO 2006042454 A1 W: AE, AG, AL, AM, CN, CO, CR, CU, GE, GH, GM, HR, LC, LK, LR, LS, NA, NG, NI, NO, SK, SL, SM, SY, YU, ZA, ZM, ZW RW: AT, BE, BG, CH,	PATENT NO. KIND  US 20060084615 A1 CN 1763030 A W0 2006042454 A1 W: AE, AG, AL, AM, AT, CN, CO, CR, CU, CZ, GE, GH, GM, HR, HU, LC, LK, LR, LS, LT, NA, NG, NI, NO, NZ, SK, SL, SM, SY, TJ, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY,	PATENT NO. KIND DATE  US 20060084615 A1 2006 CN 1763030 A 2006 W0 2006042454 A1 2006 W: AE, AG, AL, AM, AT, AU, CN, CO, CR, CU, CZ, DE, GE, GH, GM, HR, HU, ID, LC, LK, LR, LS, LT, LU, NA, NG, NI, NO, NZ, OM, SK, SL, SM, SY, TJ, TM, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ,	PATENT NO. KIND DATE  US 20060084615 A1 20060420 CN 1763030 A 20060427 W: AE, AG, AL, AM, AT, AU, AZ, CN, CO, CR, CU, CZ, DE, DK, GE, GH, GM, HR, HU, ID, IL, LC, LK, LR, LS, LT, LU, LV, NA, NG, NI, NO, NZ, OM, PG, SK, SL, SM, SY, TJ, TM, TN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE,	PATENT NO. KIND DATE  US 20060084615 A1 20060420 CN 1763030 A 20060427 W: AE, AG, AL, AM, AT, AU, AZ, BA, CN, CO, CR, CU, CZ, DE, DK, DM, GE, GH, GM, HR, HU, ID, IL, IN, LC, LK, LR, LS, LT, LU, LV, LY, NA, NG, NI, NO, NZ, OM, PG, PH, SK, SL, SM, SY, TJ, TM, TN, TR, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK,	PATENT NO. KIND DATE APPL  US 20060084615 A1 20060420 US 2 CN 1763030 A 20060426 CN 2 WO 2006042454 A1 20060427 WO 2 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, GE, GH, GM, HR, HU, ID, IL, IN, IS, LC, LK, LR, LS, LT, LU, LV, LY, MA, NA, NG, NI, NO, NZ, OM, PG, PH, PL, SK, SL, SM, SY, TJ, TM, TN, TR, TT, YU, ZA, ZM, ZW  RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE,	PATENT NO. KIND DATE APPLICAT  US 20060084615 A1 20060420 US 2004— CN 1763030 A 20060426 CN 2004— WO 2006042454 A1 20060427 WO 2005— W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, YU, ZA, ZM, ZW  RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,	PATENT NO. KIND DATE APPLICATION:  US 20060084615 A1 20060420 US 2004-9695 CN 1763030 A 20060426 CN 2004-1009 WO 2006042454 A1 20060427 WO 2005-CN16 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,	PATENT NO. KIND DATE APPLICATION NO.  US 20060084615 A1 20060420 US 2004-969571 CN 1763030 A 20060426 CN 2004-10096209 WO 2006042454 A1 20060427 WO 2005-CN1676 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,	PATENT NO. KIND DATE APPLICATION NO.  US 20060084615 A1 20060420 US 2004-969571 CN 1763030 A 20060426 CN 2004-10096209 WO 2006042454 A1 20060427 WO 2005-CN1676 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,	PATENT NO. KIND DATE APPLICATION NO. DZ  US 20060084615 A1 20060420 US 2004-969571 20  CN 1763030 A 20060426 CN 2004-10096209 20  WO 2006042454 A1 20060427 WO 2005-CN1676 20  W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, YU, ZA, ZM, ZW  RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,	PATENT NO. KIND DATE APPLICATION NO. DATE  US 20060084615 A1 20060420 US 2004-969571 200410 CN 1763030 A 20060426 CN 2004-10096209 200410 WO 2006042454 A1 20060427 WO 2005-CN1676 200510 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM -969571 A 20041020

PRAI US 2004-969571

OS CASREACT 144:381954; MARPAT 144:381954

- The present invention provides acetylated derivs. of the compound puerarin that have enhanced bioavailability and are particularly suitable for oral administration. The present invention also teaches the use of medicaments containing acetylated derivs. of puerarin that are suitable for the treatment of myocardial ischemia and for modulating blood lipid levels, dilating coronary and cerebral arteries, reducing oxygen consumption of cardiomyocytes, improving microcirculation and preventing aggregation of blood platelets.
- 2889-07-8P 882979-98-8P RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (synthesis of acetylated puerarin derivs. for improved bioavailability) 2889-07-8 CAPLUS
- CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-4)tetra-O-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

- RN 882979-98-8 CAPLUS
- $O-acetyl-\beta-D-glucopyranosyl)-$  (CA INDEX NAME)

- T. 9 ANSWER 33 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- 2006:91447 CAPLUS AN
- DN 146:62994
- A novel conformation investigation on newly synthesized compound of diethyl puerarin-7-yl phosphate
- Yuan, Jin-Wei; Chen, Xiao-Lan; Qu, Ling-Bo; Tang, Ming-Sheng; Liang, AU Rui-Ling; Zhao, Yu-Fen
  Dep. Chem., Key Lab. Chem. Biol., Zhengzhou Univ., Zhengzhou, 450052,
- CS Peop. Rep. China

## 10/563,471

```
SO Jiegou Huaxue (2006), 25(1), 78-84
CODEN: JHUADF; ISSN: 0254-5861
PB Jiegou Huaxue Bianji Weiyuanhui
DT Journal
LA English
OS CASREACT 146:62994
GI
```


AB A novel compound, di-Et puerarin-7-yl phosphate I, was synthesized through a simplified Atherton-Todd reaction for the first time. The structure of this compound was elucidated by IR, ESI-MS and NMR. Two conformations of the compound were testified by 2D NMR (HSQC and HMBC) and dynamic NMR. Conformational anal. using chemical calcn. by Gaussian 03 was carried out to obtain two preferred conformations and energy values.

IT 913627-26-6P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and conformational anal. of di-Et puerarinyl phosphate via simplified Atherton-Todd phosphorylation of puerarin and diethylphosphite)

RN 913627-26-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-[(diethoxyphosphinyl)oxy]-8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)- (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 34 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2006:77420 CAPLUS
- DN 145:310513
- TI Studies on chemical constituents of flavone from Puerariae Radix
- AU Liang, Jianwu
- CS Guangdong Light Industry School, Guangzhou, 510308, Peop. Rep. China
- SO Guangdong Huagong (2004), 31(6), 1-4 CODEN: GHUAFI; ISSN: 1007-1865
- PB Guangdongsheng Zhonghua Gongyeting Xinxi Zhongxin
- DT Journal

## 10/563,471

- LA Chinese
- AB The chemical constituents of flavone were isolated on polyamide column and determined by multilayer series connection on mass spectrum. Three chemical constitutes were isolated from Puerarin Radix by absolute ethanol, e.g., daidzein 7,4'-diglucoside, 7-xylose puerarin and puerarin. Their structures were fit to those in the document.
- IT 303114-83-2
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chemical constituents of flavone from Puerariae Radix)
- RN 303114-83-2 CAPLUS
- CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-7-( $\beta$ -D-xylopyranosyloxy)- (CA INDEX NAME)

Absolute stereochemistry.

- L9 ANSWER 35 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2006:53534 CAPLUS
- DN 144:129179
- TI Preparation of acetylsalicyloylpuerarin derivatives as platelet aggregation inhibitors
- IN Lou, Hongxiang; Liu, Lijuan; Fan, Peihong
- PA Shandong University, Peop. Rep. China
- SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 19 pp.
  - CODEN: CNXXEV
- DT Patent
- LA Chinese

	CNT 1				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1634912 CN 1314677			CN 2004-10036070	20041110
	CN 2004-10036070		20041110		
OS	CASREACT 144:129179	,			
AB				chlorinating aspirin w	ith SOCl2 in
				salicyloyl chloride;	
	acylating puerarin	in alka	line solvent	at $20-35^{\circ}$ for $1-2$ h th	ien
	refluxing for 2-3 h	, and s	eparating on	silica gel column. Th	e alkaline solvent is
	K2CO3-unsatd. THF.	7-Acet	ylsalicyloyl	puerarin was prepared a	ind showed
	platelet aggregatio	n inhib	itor activit	y superior to that of a	spirin.
ΙT	873192-72-4P 873192	-73-5P	873192-74-6P		
	RL: PAC (Pharmacolo	gical a	ctivity); SP	N (Synthetic preparation	on); BIOL
	(Biological study);	PREP (	Preparation)		
	(preparation and	l platel	et aggregati	on inhibitor activity of	f
	acetylsalicyloyl	puerari	n derivs.)		
RN	873192-72-4 CAPLUS	,			
CN	Benzoic acid, 2-(ac	etyloxy	$)-$ , $8-\beta-D-g1$	ucopyranosyl-3-(4-	

hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl ester (CA INDEX NAME)

RN 873192-73-5 CAPLUS

Benzoic acid, 2-(acetyloxy)-, 3-[4-(acetyloxy)phenyl]-8- $\beta$ -D-glucopyranosyl-4-oxo-4H-1-benzopyran-7-yl ester (CA INDEX NAME)  $_{\rm CN}$ 

Absolute stereochemistry.

873192-74-6 CAPLUS RN

Benzoic acid, 2-(acetyloxy)-, 8-(6-0-acetyl- $\beta$ -D-glucopyranosyl)-3-(4hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl ester (CA INDEX NAME)

- L9 ANSWER 36 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- 2006:10174 CAPLUS AN
- TΙ
- Synthesis and NMR characterization of diethyl puerarin-7-yl phosphate Yuan, Jin-wei; Chen, Xiao-lan; Wang, Mao-tian; Qu, Ling-bo; Zhao, Yu-fen AU
- Henan Provincial Key Lab of Bio-Chem. and Organic Chem., Dep. of

Chemistry, Zhengzhou University, Zhengzhou, 45002, Peop. Rep. China Bopuxue Zazhi (2005), 22(4), 409-415 CODEN: BOZAE2; ISSN: 1000-4556 SO PB Kexue Chubanshe DT Journal LA Chinese CASREACT 145:471276 OS Puerarin, an isoflavone compound [i.e., ΔB  $8-\beta-D-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-1-benzopyr$ one] is the bioactive component of traditional Chinese medicine puerarin lobate (wild). A novel di-Et puerarin-7-yl phosphate was synthesized by the Atherton-Todd reaction with high productive yield. It was found that the compound synthesized has two sets of NMR signals at room temperature, suggesting the existence of two conformational isomers in solution The 1H chemical shifts of the compound were assigned using two-dimensional NMR techniques, including 1H-detected heteronuclear multiple-quantum coherence and 1H-detected multiple-bond heteronuclear multiple-quantum coherence. 913627-26-6P RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and NMR characterization of di-Et puerarin phosphate (hydroxy isoflavone)) RN 913627-26-6 CAPLUS 4H-1-Benzopyran-4-one, 7-[(diethoxyphosphinyl)oxy]-8- $\beta$ -Dglucopyranosyl-3-(4-hydroxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.

2005:997009 CAPLUS

LC/ESI/MSn systems

144:208854

Kachlicki, Piotr; Marczak, Lukasz; Kerhoas, Lucien; Einhorn, Jacques; Stobiecki, Maciej Institute of Bioorganic Chemistry PAS, Poznan, 61-704, Pol. CS Journal of Mass Spectrometry (2005), 40(8), 1088-1103 CODEN: JMSPFJ; ISSN: 1076-5174 SO PB John Wiley & Sons Ltd. DT Journal English LΆ ΔB Exts. obtained from roots of three lupine species (Lupinus albus, L. angustifolius, L. luteus) were analyzed using LC/UV and LC/ESI/MSn. The expts. were performed using two mass spectrometric systems, equipped with the triple quadrupole or ion trap analyzers. Thirteen to twenty isomeric isoflavone conjugates were identified in roots of the investigated lupine species. These were di- and monoglycosides of genistein and 2'-hydroxygenistein with different patterns of glycosylation, both at oxygen and carbon atoms; some glycosides were acylated with malonic acid. It was not possible to establish the glycosylation sites of the aglycon only on the basis of the registered mass spectra; however, it was possible to differentiate C- and O-glucosides of isoflavones. Only comparison of retention times with those of standard compds. permitted to indicate the correct glycosylation pattern. In the case of diglycosides, the glycosylation pattern (O-diglucoside or O-glucosylglucoside) was

Profiling isoflavone conjugates in root extracts of lupine species with

ANSWER 37 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

L9

AN DN

AII

distinguishable on the basis of the relative intensities of daughter ions in the mass spectra of protonated mol. ions. It was not possible to elucidate the site of malonylation on the sugar moiety from mass spectra, however, protonated mols. [M+H]+ of isoflavone glucosides with different placement of the malonyl group on the sugar ring were recognized in the exts. In addition to the isoflavone glycosides, some flavone or flavonol glycosides were identified in the samples on the basis of collision-induced daughter ion spectra of the aglycon ions. A comparison of results obtained with the triple quadrupole and ion trap analyzers was done in the course of the investigations.

IT 875896-74-5 876054-92-1

RL: NPO (Natural product occurrence); BIOL (Biological study); OCCU (Occurrence)

(profiling isoflavone conjugates in root exts. of lupine species with LC/ESI/MSn systems)

RN 875896-74-5 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-( $\beta$ -D-glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 876054-92-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-( $\beta$ -D-glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-, mono(hydrogen propanedioate) (9CI) (CA INDEX NAME)

CM 1

CRN 875896-74-5 CMF C27 H30 O15

Absolute stereochemistry.

CM 2

CRN 141-82-2

CMF C3 H4 O4

HO2C-CH2-CO2H

#### RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- ANSWER 38 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- 2005:577178 CAPLUS AN
- DN146:514406
- TΙ Effect of hydroxyethylpuerarin on apoptosis and expression of p53 in focal brain
- ΑU
- Sun, Ru; Wang, Xin; Wei, Xinbing; Zhang, Xiumei; Sun, Xia; Wang, Ziying School of Medicine, Shandong University, Jinan, Shandong Province, 250012, CS Peop. Rep. China
- Zhongguo Shenghua Yaowu Zazhi (2004), 25(6), 336-338 CODEN: ZSYZFP; ISSN: 1005-1678
- PB Zhongquo Shenghua Yaowu Zazhi Bianjibu
- DT Journal
- LΑ Chinese
- Hydroxyethylpuerarin (compound N-2035) is modified in structure from puerarin, a kind of isoflavone that was extracted from Chinese traditional AΒ medicine. The protective effect of hydroxyethylpuerarin on focal brain ischemia-reperfusion injury in rats was studied. The models of focal brain ischemia reperfusion injury by middle cerebral artery occlusion (MCAO) established in Wister rats were used for HE stain,  $\bar{\text{T}}\text{UNEL}$  and determination of p53. Hydroxyethylpuerarin can significantly improve the pathol. changes and inhibit apoptosis in hippocampus CA1 area and at the same time decrease the expression of p53. Hydroxyethylpuerarin can relieve brain damage induced by focal ischemia/reperfusion in rats, which may be related to the decrease of the expression of p53 and the inhibition of apoptosis.
- 240131-05-9, Hydroxyethylpuerarin RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (effect of hydroxyethylpuerarin on apoptosis and expression of p53 in focal brain)
- 240131-05-9 CAPLUS RN
- 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-CN (2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

- 1.9 ANSWER 39 OF 79 CAPLUS COPYRIGHT 2009 ACS on SIN
- ΑN 2005:67880 CAPLUS
- 142:403975 DN
- Anti-inflammatory effect of hydroxyethylpuerarin on focal brain ΤT ischemia/reperfusion injury in rats
- Lou, Hai-Yan; Zhang, Xiu-Mei; Wei, Xin-Bing; Wang, Ru-Xia; Sun, Xia Department of Pharmacology, School of Medicine, Shandong University, ΑU
- CS
- Jinan, Shandong, 250012, Peop. Rep. China Chinese Journal of Physiology (Taipei, Taiwan) (2004), 47(4), 197-201 SO CODEN: CJPHDG; ISSN: 0304-4920

- PB Chinese Physiological Society
- DT Journal
- LΑ English
- AB The objective of this study is to investigate the anti-inflammatory effect of hydroxyethylpuerarin on focal brain ischemia injury in rats and to explore its mechanisms of action. After 24 h of reperfusion following 2 h of cerebral ischemia, the infiltration of neutrophils was observed by myeloperoxidase (MPO) activity determination, the expression of intercellular adhesion mol.-1(ICAM-1) was observed by western blot and reverse transcriptase-polymerase chain reaction(RT-PCR) anal., and the nuclear translocation and DNA binding activity of nuclear factor- $\kappa B$ (NF- $\kappa\textsc{B}\xspace)$  were observed by western blot and electrophoretic mobility shift assay (EMSA). The results showed that hydroxyethylpuerarin could obviously inhibit the MPO activity and ICAM-1 expression following 2 h of ischemia with 24 h of reperfusion. The nuclear translocation and DNA binding activity were also decreased by hydroxyethylpuerarin treatment. These results suggested that hydroxyethylpuerarin could inhibit neutrophil-mediated inflammatory response after brain ischemia reperfusion in rats. This effect may be mediated by down-regulation of ICAM-1 and NF-κB activity.
- 240131-05-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxyethylpuerarin effectively reduced myeloperoxidase activity and intercellular adhesion mol.-1 expression following focal cerebral ischemic injury in rat which may be mediated by inhibition of nuclear factor-kB activation)

240131-05-9 CAPLUS RN

CN 4H-1-Benzopyran-4-one,  $8-\beta-D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-$ (2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

#### THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 11 ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 40 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- 2005:34764 CAPLUS AN
- DN142:94062
- Preparation and pharmacological activities of C-glycosylisoflavones having alkylaminoalkoxyl substituents
- ΤN Wang, Lin; Wang, Shengqi; Peng, Tao; Lu, Qiujun; Zhu, Xiaowei; Zhang,
- Shouguo; Ren, Jianping; Li, Lu; Han, Ling; Jin, Yiguang; Che, Fengsheng Institute of Radiation Medicine, Academy of Military Medical Sciences PL, Peop. Rep. China; Hainan Yangpu New & Special Medicine Co., Ltd.
- PCT Int. Appl., 28 pp. SO
- CODEN: PIXXD2 DT Patent
- LΑ Chinese

F

FAN.	CNT	1																
	PA:	CENT	NO.			KINI	)	DATE			APPL:	ICAT:	ION I	NO.		DI	ATE	
							-									_		
PΙ	WO	2005	0031	46		A1		2005	0113		WO 2	004-	CN72	3		20	0040	702
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,

```
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
              SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
              SN, TD, TG
     CN 1566128
                                    20050119
                                                  CN 2003-148547
                             Α
     EP 1647555
                                    20060419
                                                 EP 2004-738326
                                                                            20040702
                             A1
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
81 A 20060726 CN 2004-80017384
                                                 CN 2004-80017384
     CN 1809581
                                                                            20040702
                             Α
     US 20080293642
                             A 1
                                    20081127
                                                 US 2008-563471
                                                                            20080314
                                    20030703
PRAI CN 2003-148547
                             Α
     WO 2004-CN728
                                    20040702
     MARPAT 142:94062
GT
```

```
Title compds. I (R1, R2 = H, dialkylaminopropyl, dialkylaminobutyl,
AB
     pyrrolidinoalkyl, piperidinoalkyl, etc.; R3 = H, acyl, etc.), useful for
     the treatment of various cardiocerebral vascular diseases,
     hypoxic-ischemia, treatment or prevention of diabetes mellitus and its
     complication, and chemical poisoning, in particular alcoholism, are prepared
     Thus, 4'-(3-N-morpholinopropoxy)-7-hydroxy-8-\beta-D-glucosylisoflavone
     was prepared and showed antihypoxia activity at 60 mg/kg i.p. in mice.
ΙT
     816423-75-3P 816423-76-4P 816423-77-5P
     816423-78-6P 816423-79-7P 816423-80-0P
     816423-81-1P 816423-82-2P 816423-83-3P
     816423-84-4P 816423-85-5P 816423-86-6P
     816423-87-7P 816423-88-8P 816423-89-9P
     816423-90-2P 816423-91-3P 816423-92-4P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
         (preparation and pharmacol. activities of C-glycosylisoflavones having
         alkylaminoalkoxyl substituent)
     816423-75-3 CAPLUS
     4H-1-Benzopyran-4-one, 3-[4-(3-bromopropoxy)phenyl]-8-\beta-D-
CN
     glucopyranosyl-7-hydroxy- (CA INDEX NAME)
```

Ι

## 10/563,471

RN 816423-76-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[4-(4-bromobutoxy)phenyl]-8- $\beta$ -D-glucopyranosyl-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-77-5 CAPLUS

CN  $^4\text{H-}1\text{-Benzopyran-}4\text{-one}, 8-\beta\text{-D-glucopyranosyl-}7\text{-hydroxy-}3\text{-}[4\text{-}[3\text{-}(1\text{-piperidinyl})\text{propoxy}]\text{phenyl}]- (CA INDEX NAME)$ 

Absolute stereochemistry.

RN 816423-78-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-[3-(4-morpholinyl)propoxy]phenyl]- (CA INDEX NAME)

## 10/563,471

Absolute stereochemistry.

RN 816423-79-7 CAPLUS

CN 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-80-0 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[4-[3-(diethylamino)propoxy]phenyl]-8- $\beta$ -D-glucopyranosyl-7-hydroxy- (CA INDEX NAME)

RN 816423-81-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[4-[3-(dipropylamino)propoxy]phenyl]-8-β-Dglucopyranosyl-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-82-2 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[4-[3-(dibutylamino)propoxy]phenyl]-8- $\beta$ -D-glucopyranosyl-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-83-3 CAPLUS

CN 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]- (CA INDEX NAME)

RN 816423-84-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[4-[3-(4-ethyl-1-piperazinyl)propoxy]phenyl]-8-  $\beta$ -D-glucopyranosyl-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-85-5 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-[4-(1-piperidinyl)butoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-86-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-[4-(4-morpholinyl)butoxy]phenyl]- (CA INDEX NAME)

RN 816423-87-7 CAPLUS

CN 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-[4-(1-pyrrolidinyl)butoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-88-8 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[4-[4-(diethylamino)butoxy]phenyl]-8- $\beta$ -D-glucopyranosyl-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-89-9 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[4-[4-(dipropylamino)butoxy]phenyl]-8- $\beta$ -D-

glucopyranosyl-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-90-2 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[4-[4-(dibutylamino)butoxy]phenyl]-8- $\beta$ -D-glucopyranosyl-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 816423-91-3 CAPLUS

CN 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-7-hydroxy-3-[4-[4-(4-methyl-1-piperazinyl)butoxy]phenyl]- (CA INDEX NAME)

RN 816423-92-4 CAPLUS

4H-1-Benzopyran-4-one, 3-[4-[4-(4-ethyl-1-piperazinyl)butoxy]phenyl]-8β-D-glucopyranosyl-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 41 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- 2004:442029 CAPLUS AN
- DN 142:257695
- Chemical constituents from the leaves of Dalbergia hainanensis
- Zhang, Peicheng; Wu, Yan; Yu, Dequan ΑIJ
- Institute of Materia Medica, Chinese Academy of Medical Science and Peking CS Union Medical College, Beijing, 100050, Peop. Rep. China Zhongguo Zhongyao Zazhi (2003), 28(6), 527-530
- SO CODEN: ZZZAE3; ISSN: 1001-5302
- PB Zhongguo Yaoxuehui
- DT Journal
- LAChinese
- AΒ The chemical constituents from the leaves of Dalbergia hainanensis were studied. Compds. were isolated by chromatog. techniques on silica gel and polyamide column. Their structures were elucidated by chemical and spectroscopic methods. Thirteen compds. were identified as 8-C-glucosyl-7-methoxy-4',5-dihydroxyisoflavone, 8-C-glucosyl-7,4',5-trihydroxyisoflavone, 2-hydroxy-5-methoxy biochanin A, formononetin , 3,5-dimethoxy-4-hydroxybenzaldehyde, 1-O-β-D-glucopyranosyl-(2S,3S,4R,8Z)-2-[(2R)-2-hydroxyl docosylamino]-8-octadecene-1,3,4-triol, friedelin, taraxerol,  $3\beta-hydroxy-glutin-5-ene$  , ursolic acid,  $\beta-sitosterol$  , daucosterol, and lupeol. All the compds. were isolated from the plant for the first time.
- 52448-12-1
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (constituents from leaves of Dalbergia hainanensis)
- 52448-12-1 CAPLUS
- CN 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-5-hydroxy-3-(4hydroxyphenyl)-7-methoxy- (CA INDEX NAME)

- ANSWER 42 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN T. 9
- 2004:376414 CAPLUS AN
- DN140:368689
- Application of hydroxyethyl-puerarin in preparing the new drug for TΙ treating cerebrovascular diseases
- Zuo, Chunxu; Zhang, Xiumei; Zhong, Ying; Yang, Shangjun; Wang, Ziying; Wang, Ju; Chen, Jianqiang; Li, Anguo; Liu, Jikai IN
- PA
- Zhenping Pharmaceutical Factory, Shanxi, Peop. Rep. China Faming Zhuanli Shenqing Gongkai Shuomingshu, 11 pp. SO CODEN: CNXXEV
- Patent
- Chinese TιA

FAN.CNT 1

T. TATA	~ TA T	_				
	PATENT NO.			DATE	APPLICATION NO.	DATE
PI	CN	1394603	A	20030205	CN 2002-135352	20020809
	CN	1186026	C	20050126		
PRAI	CN	2002-135352		20020809		

- AΒ The invention relates to the application of hydroxyethyl-puerarin in preparing the new medical prepns. for treating cerebrovascular ischemia. TT 240131-05-9

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(application of hydroxyethyl-puerarin in preparing the new drug for treating cerebrovascular diseases)

- 240131-05-9 CAPLUS
- 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME) CN

- ANSWER 43 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2004:20483 CAPLUS 1.9
- AN
- DN 140:71053

```
Compounds useful for the inhibition of mitochondrial aldehyde
     dehydrogenase (ALDH-2) and modulating alcohol consumption, dependence and
ΤN
     Keung, Wing Ming; Vallee, Bert L.; Gao, Guangyao
PA
     The Endowment for Research in Human Biology, Inc., USA
     PCT Int. Appl., 67 pp.
     CODEN: PIXXD2
DT
     Patent.
\mathrm{L} A
     English
FAN.CNT 1
                                              APPLICATION NO.
                                                                      DATE
     PATENT NO.
                          KIND
                                 DATE
PΙ
     WO 2004002470
                           A1
                                 20040108
                                              WO 2003-US20584
                                                                      20030627
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM,
                                      DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL,
                          IN, IS, JP,
                                      KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
                          LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
         RW: GH, GM, KE,
                              TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             KG, KZ, MD, RU,
             FI, FR, GB,
                          GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
     CA 2491089
                                 20040108
                                              CA 2003-2491089
                                                                      20030627
                           A 1
     AU 2003247844
                                 20040119
                                              AU 2003-247844
                                                                      20030627
                           A1
     AU 2003247844
                           В2
                                 20090122
     US 20040068003
                           A1
                                 20040408
                                              US 2003-609120
                                                                      20030627
     US 7368434
                                 20080506
                           В2
     EP 1542675
                                              EP 2003-762244
                           A1
                                 20050622
                                                                      20030627
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1671373
                                 20050921
                                              CN 2003-817905
                                                                      20030627
                           A
     JP 2006501180
                                 20060112
                                              JP 2004-518118
                                                                      20030627
     NZ 537366
                                 20071221
                                              NZ 2003-537366
                                                                      20030627
     MX 2005000122
                                 20051214
                                              MX 2005-122
                                                                      20050103
                           Α
PRAI US 2002-391907P
                                 20020627
     WO 2003-US20584
                                 20030627
                           W
OS
     MARPAT 140:71053
     The present invention provides novel antidipsotropic compds. The
     invention further provides methods of inhibiting ALDH-2 using the compds.
     described herein. Methods for modulating alc. consumption, alc.
     dependence and/or alc. abuse by administering the compds. of the invention
     to an individual are also provided. The present invention further
     provides a rationale for designing addnl. novel antidipsotropic compds.
     Hexzein, given orally, reduced ethanol intake in hamsters.
     640275-77-0P 640275-88-3P
     RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
     BIOL (Biological study); PREP (Preparation)
        (antidipsotropic compds. useful for inhibition of mitochondrial
        aldehyde dehydrogenase (ALDH-2) and modulating alc. consumption,
        dependence and abuse)
     640275-77-0 CAPLUS
RN
     4H-1-Benzopyran-4-one, 7-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-
CN
     yl)butoxy]-8-\beta-D-glucopyranosyl-3-(4-hydroxyphenyl)- (9CI) (CA INDEX
```

RN 640275-88-3 CAPLUS

Hexanoic acid,  $6-[[8-\beta-D-qlucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-$ 1-benzopyran-7-yl]oxy]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 44 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN T. 9

AN 2003:645702 CAPLUS

140:138710 DN

TTSynthesis of daidzin analogues as potential agents for alcohol abuse

ΑU Gao, Guang-Yao; Li, Dian-Jun; Keung, Wing Ming

Center for Biochemical and Biophysical Science and Medicine and Department CS of Psychiatry at Massachusetts Mental Health Center, Harvard Medical School, Boston, MA, 02115, USA

SO Bioorganic & Medicinal Chemistry (2003), 11(18), 4069-4081 CODEN: BMECEP; ISSN: 0968-0896

Elsevier Science Ltd. PB

DT Journal

T.A English

CASREACT 140:138710 OS

AB Daidzin, the active principle of an herbal remedy for 'alc. addiction', has been shown to reduce alc. consumption in all laboratory animals tested to date. Correlation studies using structural analogs of daidzin suggests that it acts by raising the monoamine oxidase (MAO)/mitochondrial aldehyde dehydrogenase (ALDH-2) activity ratio (J. Med. Chemical 2000, 43, 4169). Structure-activity relationship (SAR) studies on the 7-0-substituted analogs of daidzin have revealed structural features important for ALDH-2and MAO inhibition (J. Med. Chemical 2001, 44, 3320). We here evaluated effects of substitutions at 2, 5, 6, 8, 3' and 4' positions of daidzin on its potencies for ALDH-2 and MAO inhibition. Results show that analogs with 4'-substituents that are small, polar and with hydrogen bonding capacities are most potent ALDH-2 inhibitors, whereas those that are non-polar and with electron withdrawing capacities are potent MAO inhibitors. Analogs with a 5-OH group are less potent ALDH-2 inhibitors but are more potent MAO inhibitors. All the 2-, 6-, 8- and 3'-substituted analogs tested so far do not inhibit ALDH-2 and/or have decreased potencies for MAO inhibition. This, together with the results obtained from previous studies, suggests that a potent antidipsotropic analog would be a 4',7-disubstituted isoflavone. The 4'-substituent should be small, polar, and with hydrogen bonding capacities such as, -OH and -NH2; whereas the 7-substituent should be a straight-chain alkyl with a terminal polar function such as -(CH2)n-OH with  $2 \le n \le 6$ , -(CH2)n-COOH with  $5 \le n \le 10$ , or -(CH2)n-NH2 with  $n \ge 4$ .

640275-88-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and structure-activity relationship of daidzin analogs as potential agents for alc. abuse)

RN 640275-88-3 CAPLUS

Hexanoic acid, 6-[[8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-CN 1-benzopyran-7-yl]oxy]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

640275-77-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synthesis and structure-activity relationship of daidzin analogs as potential agents for alc. abuse) 640275-77-0 CAPLUS

RN

4H-1-Benzopyran-4-one, 7-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butoxy]-8- $\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)- (9CI) (CA INDEX CN

Absolute stereochemistry.

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 23 ALL CITATIONS AVAILABLE IN THE RE FORMAT

- ANSWER 45 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2003:627030 CAPLUS L9
- AN
- DN139:323705
- ΤI
- Total synthesis of puerarin, an isoflavone C-glycoside Lee, David Y. W.; Zhang, Wu-Yan; Karnati, Vishnu Vardhan R. ΑU
- Harvard Medical School, Bioorganic and Natural Products Laboratory, McLean Hospital, Belmont, MA, 02478, USA Tetrahedron Letters (2003), 44(36), 6857-6859 CS
- CODEN: TELEAY; ISSN: 0040-4039
- PB Elsevier Science B.V.
- DT Journal
- LΑ English
- CASREACT 139:323705 OS

AB We completed the first total synthesis of puerarin, an isoflavone C-glycoside. The key intermediate,  $\beta\text{-D-glucopyranosyl-2,6-dimethoxybenzene, was obtained by coupling of 2,6-dimethoxyphenyl lithium with perbenzyl glycopyranolactone in 56% yield. Condensation of I with p-methoxybenzaldehyde gave the chalcone.$ 

yield. Condensation of I with p-methoxybenzaldehyde gave the chalcone. The acetyl protected chalcone was cyclized with Tl(NO3)3 to yield II. Demethylation of II was accomplished by refluxing with TMSI in CH3CN to give puerarin.

IT 69655-50-1P 69655-53-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of puerarin, an isoflavone C-glycoside using

 $\beta$ -D-glucopyranosyl-2,6-dimethoxybenzene as the key chiral synthon)

RN 69655-50-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-methoxy-3-(4-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 69655-53-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-methoxy-3-(4-methoxyphenyl)-8-(2,3,4,6-tetra-0-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME)

615275-47-3P

RL: SPN (Synthetic preparation); PREP (Preparation) (synthesis of puerarin, an isoflavone C-glycoside using  $\beta$ -D-glucopyranosyl-2,6-dimethoxybenzene as the key chiral synthon)

615275-47-3 CAPLUS RN

4H-1-Benzopyran-4-one,  $8-\beta-D-glucopyranosyl-3-(4-hydroxyphenyl)-7-$ CN methoxy- (CA INDEX NAME)

Absolute stereochemistry.

#### RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 46 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2003:599432 CAPLUS
- 139:381034 DN
- ТΤ
- Conformational study on 8-C-glucosyl-prunetin by dynamic NMR spectroscopy Zhang, Pei-Cheng; Wang, Ying-Hong; Liu, Xin; Yi, Xiang; Chen, Ruo-Yun; Yu, ΑU De-Ouan
- CS Institute of Material Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China Huaxue Xuebao (2003), 61(7), 1157-1160 CODEN: HHHPA4; ISSN: 0567-7351
- SO
- PB Kexue Chubanshe
- DT Journal
- Chinese LA
- OS CASREACT 139:381034
- By means of variable temperature dynamic NMR spectra, conformation of AB 8-C-glucosyl prunetin, isolated from the leaves of Dalbergia hainanensis (Leguminosae), and other 8-C-glucosyl flavones was studied. The restricted rotation around the 1''-C(sp3)-8-C(sp2) bond in the C-glucosides isoflavonoid results in two main conformers (syn and anti). With the help of Mol. Mechanics (MM) calcn., the preferred conformation A of 8-C-glucosyl prunetin has 1''-H gauche to the 7-OCH3. The barrier to rotation was 75.66 kJ/mol. This result agrees with the calculated value 71.48kJ/mol of free energy of activation for the interconversion between the conformers.

Absolute stereochemistry.

II 69655-50-1P 240131-04-8P 623900-91-4P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (conformational study on 8-C-glucosyl-prunetin by dynamic NMR
 spectroscopy)
RN 69655-50-1 CAPLUS
CN 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-7-methoxy-3-(4-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.

623900-91-4 CAPLUS

4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-propoxy-3-(4-CNpropoxyphenyl) - (CA INDEX NAME)

- ANSWER 47 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2003:438997 CAPLUS T. 9
- AN
- 139:148617
- Profiling and Quantification of Isoflavonoids in Kudzu Dietary Supplements by High-Performance Liquid Chromatography and Electrospray Ionization Tandem Mass Spectrometry
- Prasain, Jeevan K.; Jones, Kenneth; Kirk, Marion; Wilson, Landon; Smith-Johnson, Michelle; Weaver, Connie; Barnes, Stephen
- Department of Pharmacology and Toxicology, Purdue-UAB Botanicals Center for Age-Related Disease and Comprehensive Cancer Center Mass Spectrometry CS Shared Facility, University of Alabama at Birmingham, Birmingham, AL, 35294, USA
- Journal of Agricultural and Food Chemistry (2003), 51(15), 4213-4218 SO CODEN: JAFCAU; ISSN: 0021-8561
- American Chemical Society
- DT Journal
- TιA English
- The kudzu vine (Pueraria sp.) is a rich source of isoflavones. Dietary supplements based on kudzu have become com. available. In the present study, LC coupled with neg. and pos. electrospray ionization tandem  ${\tt mass}$ spectrometry (MS/MS) and diode array detection (DAD) was used for the detection and characterization of isoflavonoids in kudzu dietary supplements (KDS). The MS/MS spectrum of the protonated ion of puerarin showed characteristic product ions of the C-glycoside unit itself, whereas daidzin generated an abundant Y+0 aglycon ion in its product ion spectrum. A base peak due to the loss of 120 Da  $[M + H - 120] + \hat{i}s$  the diagnostic ion for C-qlycosides. Neutral loss scans allowed for the detection of other C- and O-glycosides in the methanolic extract of KDS, and their structures have been proposed. The concentration of isoflavonoids in the methanolic extract of com. available KDS was quantified by using DAD-HPLC. Puerarin, rather

Absolute stereochemistry.

# RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 48 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2002:609154 CAPLUS T. 9 AN 138:238346 Study on the preparation of 7,4'-di-O-hydroxyethylpuerarin Hou, Dianjie; Wang, Jianwu; Sun, Jianlong TΙ ΑIJ CS College of Chemistry and Chemical Engineering, Shandong University, Jinan, 250100, Peop. Rep. China SO Zhongguo Yaowu Huaxue Zazhi (2002), 12(2), 103-104 CODEN: ZYHZEF; ISSN: 1005-0108 PB Zhongguo Yaowu Huaxue Zazhi Bianjibu  $\mathsf{DT}$ Journal Chinese LA CASREACT 138:238346 OS AB 7,4'-Di-O-hydroxyethylpuerarin was prepared by two different methods such as hydroxyethylation with 2-chloroethanol or 2- bromoethanol and oxirane method. The hydroxyethylation of puerarin with ethylene oxide was the more practical and convenient method. 240131-05-9P, 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2hydroxyethoxy)phenyl]-RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of 7,4'-di-O-hydroxyethylpuerarin by hydroxyethylation of puerarin and with oxirane) RN 240131-05-9 CAPLUS 

- ANSWER 49 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 2002:560124 CAPLUS T. 9
- AN
- DN 137:337496
- TΙ
- Conformational study of 8-C-glucosyl-prunetin by dynamic NMR spectroscopy Zhang, Pei Cheng; Wang, Ying Hong; Liu, Xin; Yi, Xiang; Chen, Ruo Yun; Yu, AU
- CS Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China Chinese Chemical Letters (2002), 13(7), 645-648
- SO CODEN: CCLEE7; ISSN: 1001-8417
- Chinese Chemical Society
- DT Journal
- LA English
- AB By variable temperature NMR spectra, conformation of 8-C-glucosyl prunetin, isolated from the leaves of Dalbergia hainanensis (Leguminosae), was studied. The restricted rotation around the C (sp3)-C (sp2) bond in the C-glucosides isoflavonoid results in two main conformers (syn and anti). With the help of MM calcn., the preferred conformation A has H-1'' gauche to the 7-OMe. The barrier to rotation was 18.1 kcal/mol. This result agrees with the calculated value 16.2 kcal/mol of free energy of activation for the interconversion between the conformers.
- 52448-12-1, 8-C-Glucosyl prunetin
  - RL: PRP (Properties)
    - (conformational study of 8-C-glucosyl-prunetin by dynamic NMR spectroscopy)
- RN 52448-12-1 CAPLUS
- 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-5-hydroxy-3-(4hydroxyphenyl)-7-methoxy- (CA INDEX NAME)

## Absolute stereochemistry.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 50 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN T. 9 2001:251181 CAPLUS AN

#### 10/563,471

- DN 135:16768
- Isoflavonoids and alkaloids from Spartidium saharae
- Abdel-Halim, Osama B.; Abdel-Fattah, Hosny A.; Halaweish, Fathi T.; Halim, ΑIJ Ahmed F.
- CS Dept. of Chemistry, South Dakota State Univ., SD, USA
- Natural Product Sciences (2000), 6(4), 189-192
- CODEN: NPSCFB; ISSN: 1226-3907 Korean Society of Pharmacognosy PB
- DT Journal
- English LΑ
- A new isoflavone, (+)-4'-0-methyl-8-C- $\beta$ -D-glucopyranosylgenistein, AB was isolated from the aerial parts of Spartidium saharae together with the known isoflavone (+)-8-C- $\beta$ -D-glucopyranosylgenistein as well as the dipiperidine alkaloids (+)-ammodendrine and (+)-N-acetylhystrine. Details of their structure elucidation are based on chemical and spectroscopic methods. N-formylammodendrine was detected by GC-MS. The potential chemotaxonomic value of the alkaloid content is discussed. Cytotoxic activity has been determined for both alc. extract and isolated compds.
- ΤТ 342655-86-1P RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
  - (isolation from Spartidium saharae and structural elucidation of)
- RN 342655-86-1 CAPLUS
- CN4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-5,7-dihydroxy-3-(4methoxyphenyl) - (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 16 ALL CITATIONS AVAILABLE IN THE RE FORMAT

- Ь9 ANSWER 51 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- 2001:87754 CAPLUS AΝ
- DN 134:307892
- Isoflavones and a saponin from Crotalaria thebaica (Del.) DC growing in Egypt
- Ibraheim, Z. Z.; Khalifa, A. A. ΑIJ
- CS Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, Egypt
- SO Bulletin of Pharmaceutical Sciences, Assiut University (2000), 23(2), 177-186
  - CODEN: BPAUEC; ISSN: 1110-0052
- Assiut University Press
- DT Journal
- LΑ English
- Further investigation of the dried aerial parts of Crotalaria thebaica (Del.) DC. led to the isolation of two isoflavone aglycons; Biochanin A and Genistein, an isoflavone-O-glucoside; Biochanin  $A-7-0-\beta$ -glucoside, 2 isoflavone C-glycosides identified as 8-C-glucosyl genistein and 6,8-di-C-glucosyl biochanin A and a saponin glycoside identified as robinioside C Me ester. The identification of the isolated compds. was based on chemical and spectral studies.
- 335139-12-3, 6,8-Di-C-glucosyl biochanin A RL: BOC (Biological occurrence); BSU (Biological study, unclassified);

RN

BIOL (Biological study); OCCU (Occurrence) (isoflavones and a saponin from Crotalaria thebaica) 335139-12-3 CAPLUS

 $\texttt{4H-1-Benzopyran-4-one, 6,8-di-} \\ \beta-D-\texttt{glucopyranosyl-5,7-dihydroxy-3-(4-dihydroxy-3$ CN methoxyphenyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

T. 9 ANSWER 52 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

2001:31340 CAPLUS AN

DN 134:95502

Compositions and methods for treating or preventing osteoporosis TΙ

INPrince, Richard Lewis; Min, Xu

University of Western Australia, Australia; Guanqzhou University of Traditional Chinese Medicine

SO PCT Int. Appl., 93 pp.

CODEN: PIXXD2

Patent

English LΑ

PATENT NO.					KIND		DATE			APPLICATION NO.					DATE					
	PI	PI WO 2001001996 WO 2001001996				A1 A9		20010111		WO 2000-AU737			20000629							
			W:	CR, HU, LU, SD,	CU, ID, LV, SE,	CZ, IL, MA, SG,	DE, IN, MD,	DK, IS, MG,	AU, DM, JP, MK, SL,	DZ, KE, MN,	EE, KG, MW,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NO,	GD, LC, NZ,	GE, LK, PL,	GH, LR, PT,	GM, LS, RO,	HR, LT, RU,	
	PRAT	AU	RW:	GH, DE, CF,	DK, CG,	KE, ES,	FI,	FR,	MZ, GB, GN,	GR, GW,	IE,	ΙT,	LU,	MC,	NL,	PT,				

AB The invention relates to a therapeutic composition and method for treating osteoporosis and other calcium, and/or estrogen related disorders. Examples are given for treating osteoporosis with exts. of plants such as Epimedium koreanum, Salvia miltiorrhiza, Asragalus membranaceus, Pueraria

thomsonii, and Psoralea coryliofolia. 24562-39-8, Puerarin diacetate 92117-94-7, 4'-Methoxypuerarin

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (herb medicine exts. for treating or preventing osteoporosis)

24562-39-8 CAPLUS

4H-1-Benzopyran-4-one,  $8-(6-0-acetyl-\beta-D-qlucopyranosyl)-3-[4-$ (acetyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

92117-94-7 CAPLUS RN

4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-(4-methoxyphenyl)- (CA INDEX NAME) CN

Absolute stereochemistry.

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 5 ALL CITATIONS AVAILABLE IN THE RE FORMAT

- ANSWER 53 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN L9
- 2000:761931 CAPLUS AN
- DN 133:325492
- Breast-enlarging agent containing Pueraria root products
- IN Hirose, Katsutoshi; Katayama, Masato; Hirata, Naonori
- PAKobe Tennenbutsu Kagaku K. K., Japan
- SO Jpn. Kokai Tokkyo Koho, 9 pp. CODEN: JKXXAF
- DT Patent
- TιA Japanese

FAN.CNT 1

PA	ATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
PI JE	2000302667	A	20001031	JP 1999-115773	19990423		
PRAI JE	1999-115773		19990423				

The invention relates to a breast-enlarging agent containing Pueraria root or its product, especially Pueraria lobata or Pueraria thomsonii, containing isoflavones. A powder of Puerariae Radix root was combined with vaseline to obtain an ointment. The agent may further use for treatment and prevention of menopausal syndrome, skin-whitening, or hair growth-stimulation.

303114-83-2 ΙT

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(breast-enlarging agent containing Pueraria root products)

RN 303114-83-2 CAPLUS 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-3-(4-hydroxyphenyl)-7- $(\beta-D-xylopyranosyloxy)-$  (CA INDEX NAME)

Absolute stereochemistry.

- L9 ANSWER 54 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 1999:382906 CAPLUS
- DN 131:179773
- Improvement of ocular blood flow and retinal functions with puerarin TΤ analogs
- Xuan, Bo; Zhou, Yue-Hua; Yang, Rua-Lin; Li, Na; Min, Zhi-Da; Chiou, George ΑU C. Y.
- Institute of Ocular Pharmacology and Department of Medical Pharmacology CS and Toxicology, Texas A&M Health Science Center, College of Medicine, College Station, TX, USA
- Journal of Ocular Pharmacology and Therapeutics (1999), 15(3), 207-216 SO CODEN: JOPTFU; ISSN: 1080-7683
- PB Mary Ann Liebert, Inc.
- DT Journal
- English LΑ
- AB Ischemic retinopathy and, particularly, age-related macular degeneration (AMD) are difficult eye diseases to treat. Since the etiol. of these diseases is inadequate blood circulation in the retina and choroid, drugs which can improve blood circulation to these tissues should be beneficial to these diseases. Since fovea is a vascular, AMD is closely related to choroidal vascular abnormalities, and drugs which show strong effects to increase choroidal blood flow would be particularly useful. Puerarin and all its derivs., except ET (puerarin disubstituted with -CH2CH2OH), showed marked increase of choroidal blood flow at various time periods. Even ET showed a tendency to increase choroidal blood flow, though it was not statistically significant. As for b-wave recovery, all puerarin analogs showed strong recovery of retinal function after ischemic insult for 30 min. These results indicate that puerarin analogs could be used for the treatment of ischemic retinopathy, and AMD in particular.  $69655-50-1\ 240131-04-8\ 240131-05-9$

240131-07-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(improvement of ocular blood flow and retinal functions with puerarin analogs)

RN 69655-50-1 CAPLUS

4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-methoxy-3-(4methoxyphenyl) - (CA INDEX NAME)

RN 240131-04-8 CAPLUS CN 4H-1-Benzopyran-4-one, 7-ethoxy-3-(4-ethoxyphenyl)-8- $\beta$ -D-glucopyranosyl- (CA INDEX NAME)

Absolute stereochemistry.

RN 240131-05-9 CAPLUS

CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 240131-07-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-[2,3,4-tri-0-acetyl-6-0-(triphenylmethyl)- $\alpha$ -D-galactopyranosyl]- (CA INDEX NAME)

LA

GΙ

Chinese

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 55 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 1999:353528 CAPLUS AN 131:199898 DN TΙ Preparation and bioactivity of puerarin derivatives ΑU Yang, Ruolin; Li, Na; Bo, Xuan; Chiou, Geroge C. Y.; Min, Zhida Department of Natural Pharmaceutical Chemistry, China Pharmaceutical CS University, Nanjing, 210009, Peop. Rep. China Zhongguo Yaoke Daxue Xuebao (1999), 30(2), 81-85 SO CODEN: ZHYXE9; ISSN: 1000-5048 PB Zhongguo Yaoke Daxue DT Journal

Title compds. I (R = CH3, CH3CH2, H, HOCH2CH2; R1 = CH3, CH3CH2, CH(CH3)2, CH2CO2CH2CH3, CH2COH3, CH2CH2OH, H; R2 = H, COC6H5, C(C6H5)3) were prepared from puerarin (active component in Pueraria lobata (Willd.) Ohwi) in enhancing bioactivities. The new derivs. were named as 7.4'-di-O-Et puerarin (G2), 4'-O-Et puerarin (G3), 4'-O-iso-Pr puerarin (G4), 4'-O-ethoxycarbonylmethylene puerarin (G5), 4'-O-methoxymethylene puerarin (G6), 7, 4'-di-O-hydroxyethyl puerarin (G7), 6'-O-benzoxy puerarin (G8) and 6" tribenzylmethyl puerarin (G9). The two known derivs. were 7.4'-di-O-Me puerarin (G1) and hexa-O-acetyl puerarin (G10). Effects of G9 and G10 on the blood flow in the choroid, retina, ciliary body and iris of New Zealand rabbit were studies and their effects were better than those of puerarin.

IT 2889-07-8P 69655-50-1P 240131-04-8P 240131-05-9P 241824-63-5P 241824-64-6P

240131-05-9P 241824-63-5P 241824-64-6P 241824-65-7P 241824-66-8P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and bioactivity of puerarin derivs.)

RN 2889-07-8 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-1)

tetra-O-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 69655-50-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-7-methoxy-3-(4-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 240131-04-8 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-ethoxy-3-(4-ethoxyphenyl)-8- $\beta$ -D-glucopyranosyl- (CA INDEX NAME)

Absolute stereochemistry.

N 240131-05-9 CAPLUS

CN 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-(2-hydroxyethoxy)-3-[4-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)

241824-63-5 CAPLUS RN

4H-1-Benzopyran-4-one, 3-(4-ethoxyphenyl)-8- $\beta$ -D-glucopyranosyl-7-hydroxy- (CA INDEX NAME)  $_{\rm CN}$ 

Absolute stereochemistry.

241824-64-6 CAPLUS RN

4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-(1-methylethoxy)phenyl]- (CA INDEX NAME) CN

Absolute stereochemistry.

RN

241824-65-7 CAPLUS Acetic acid, [4-(8- $\beta$ -D-glucopyranosyl-7-hydroxy-4-oxo-4H-1-benzopyran-3-yl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME) CN

- ANSWER 56 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 1999:30508 CAPLUS
- DN130:246227
- Urinary and biliary metabolites of daidzin, daidzein and puerarin in rats Yasuda, Takaaki; Ohsawa, Keisuke ΤI
- ΑU
- Tohoku College of Pharmacy, Miyagi, 981, Japan CS
- International Congress Series (1998), 1157(Towards Natural Medicine SO Research in the 21st Century), 273-283 CODEN: EXMDA4; ISSN: 0531-5131
- PΒ Elsevier Science B.V.
- DТ Journal
- LAEnglish
- In this study the urinary and biliary metabolites (M1-M7) of orally administered daidzin, daidzein and puerarin (major ingredients of the roots of Pueraria lobata) were isolated from rats and their structures were determined Total cumulative amts. of the metabolites excreted in the urine during 48 h and in the bile during 36 h after oral administration of daidzin, daidzein and puerarin were estimated resp.
- 163128-95-8 163128-96-9
  - RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
    - (urinary and biliary metabolites of daidzin, daidzein and puerarin in rats)
- RN 163128-95-8 CAPLUS
- 4H-1-Benzopyran-4-one,  $8-\beta-D-glucopyranosyl-7-hydroxy-3-[4-1]$ (sulfooxy)phenyl]- (CA INDEX NAME)

163128-96-9 CAPLUS RN

CN $\beta$ -D-Glucopyranosiduronic acid,

 $8-\beta$ -D-qlucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl (CA INDEX NAME)

- ANSWER 57 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 1998:697258 CAPLUS T. 9
- AN
- DN 130:85991
- Identification of isoflavones in the roots of Pueraria lobata ТΤ
- Rong, Haojing; Stevens, Jan F.; Deinzer, Max L.; De Cooman, Luc; De AU Keukeleire, Denis
- CS Faculty Pharmaceutical Sciences, University Gent, Ghent, B-9000, Belg.
- Planta Medica (1998), 64(7), 620-627 CODEN: PLMEAA; ISSN: 0032-0943 SO
- PBGeorg Thieme Verlag
- DT Journal
- English LΆ AB The isoflavones of the roots of P. lobata (Puerariae Radix) were investigated by HPLC coupled to photodiode array (PDA) and to mass spectroscopy (MS) using atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI) in combination with collision-activated decomposition (CAD) (HPLC-APCI-CAD-MS or ESI-CAD-MS) for identification of glycosides and HPLC-APCI-CAD-MS for identification of aglycons. The major glycosides are derived from daidzein and most are 8-C-glycosides. 3'-Hydroxypuerarin 4'-O-deoxyhexoside and 3'-methoxy-6''-O-D-xylosylpuerarin were identified as new constituents. MS data were obtained for puerarin-4'-0-D-glucoside, 3'-hydroxypuerarin, puerarin, 3'-methoxypuerarin, 6''-O-D-xylosylpuerarin, daidzin and 3'-methoxydaidzin , which were previously characterized by NMR anal. Isoflavones identified in Puerariae Radix comprise 3'-methoxydaidzein, genistein, daidzein 7-0-Me ether, 3'-methoxydaidzein 7-0-Me ether or

3'-methoxyformononetin and biochanin A, while previous characterization of daidzein and formonometin was substantiated by MS data. The structure of one compound could not be established by MS techniques. The estrogenic activity was mainly located in the aglycon fraction.

117047-08-2P

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(isoflavones of roots of Pueraria lobata)

117047-08-2 CAPLUS

CN 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-3-[4-( $\beta$ -Dglucopyranosyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

### RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 58 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 1996:167556 CAPLUS L9

ΑN

DN 124:352436

OREF 124:65253a,65256a

TΙ Pueraria lobata. A medicinal plant against alcoholism?

Saller, Reinhard; Reichling, Juergen ΑU

CS Dep. Inn. Med., Univ. Zuerich, Zurich, CH-8091, Switz.

Deutsche Apotheker Zeitung (1996), 136(9), 25-7

CODEN: DAZEA2; ISSN: 0011-9857

PB Deutscher Apotheker Verlag

DТ Journal

LΑ German

The origin, the content, the pharmacol. effects and the inhibition of alc. AB metabolism of the Chinese drug Pueraria lobata is presented.

117047-08-2

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (crude drugs from Pueraria roots against alcoholism)

117047-08-2 CAPLUS

4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-3-[4-( $\beta$ -Dglucopyranosyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

## 10/563,471

Ь9

RN CN

ANSWER 59 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

```
1996:116266 CAPLUS
124:170642
AN
DN
OREF 124:31555a,31558a
TΙ
     A new isoflavone C-glycoside from Cassia siamea
     Shafiullah, M.; Parveen, M.; Kamil, M.; Ilyas, M.
Department Chemistry, Aligarh Muslim University, Aligarh, 202002, India
ΑU
CS
SO
     Fitoterapia (1995), 66(5), 439-41
     CODEN: FTRPAE; ISSN: 0367-326X
     Inverni della Beffa SpA
PB
DT
     Journal
LΑ
     English
     A novel isoflavone glycoside was isolated from the leaves of C. siamea and
     characterized as 2',4',5,7-tetrahydroxy-8-C-glucosylisoflavone
      (2'-hydroxygenistein 8-C-glucoside) .
     173866-80-3P 173866-81-4P
     RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
```

4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[2,4-bis(acetyloxy)phenyl]-5-hydroxy-8-(2,3,4,6-tetra-0-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX

NAME)
Absolute stereochemistry.

173866-80-3 CAPLUS

(preparation and properties of)

RN 173866-81-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-(2,4-dimethoxyphenyl)-8-β-D-glucopyranosyl-5,7-dimethoxy- (CA INDEX NAME)

ANSWER 60 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN T. 9

AN 1995:808056 CAPLUS

DN123:208469

OREF 123:36939a,36942a

Skin-lightening cosmetics containing isoflavone glucosides extracted from TΙ Pueraria lobata roots

Shibuya, Jusuke; Nishizawa, Yoshinori IN

PA

Kao Corp, Japan Jpn. Kokai Tokkyo Koho, 7 pp. SO

CODEN: JKXXAF

Patent

LA Japanese

FAN

FAN.CNI I						
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
PI JP 07157494	A	19950620	JP 1993-305073	19931206		
JP 3271840	B2	20020408				
PRAI JP 1993-305073		19931206				

MARPAT 123:208469 OS

Skin-lightening cosmetics contain isoflavone glycosides (I) [R1 = apiosyl, glucosyl or H; R2 = H or OH; R3 = H or glucosyl] extracted from P. lobata roots. As an example, a cream contained glycerol monostearate 5.0, polyethylene glycol monostearate 2.0, squalane 8.0, glycerol trioctanoate 8.0, stearyl alc. 5.5, di-Me polysiloxane 0.2, propylene glycol 5.0, di-Na EDTA 0.1, kojic acid 1.5, 6'-O-apiosylpuerarin-4'-O-glucoside 0.2, Na citrate 1.0, preservatives, perfumes, and ion-exchanged water to 100%. The compns. also prevented sunlight-related liver-spot and ephelis. 168035-01-6P

RL: BUU (Biological use, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Skin-lightening cosmetics containing isoflavone glucosides extracted from Pueraria lobata roots) 168035-01-6 CAPLUS

RN

4H-1-Benzopyran-4-one, 8-(6-0-D-apio- $\beta$ -D-furanosyl- $\beta$ -D-CN  $\verb|glucopyranosyl| -3 - [4 - (\beta - D - glucopyranosyloxy)| phenyl] -7 - hydroxy- (CA) - (CA)$ INDEX NAME)

ANSWER 61 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN T. 9

AN 1995:441848 CAPLUS

122:281356 DN

OREF 122:51003a,51006a

Urinary and biliary metabolites of puerarin in rats TT

ΑU Yasuda, Takaaki; Kano, Yoshihiro; Saito, Ken-ichi; Ohsawa, Keisuke

CS

Tohoku Coll. Pharm., Sendai, 981, Japan Biological & Pharmaceutical Bulletin (1995), 18(2), 300-3 SO

CODEN: BPBLEO; ISSN: 0918-6158

PB Pharmaceutical Society of Japan

DT Journal

English LA

Examination was made of the urinary and biliary excretion of the metabolites of AB puerarin, the major component of the roots of Pueraria lobata Ohwi (Leguminosae) in rats. The urine of rats administered puerarin orally contained puerarin and four major metabolites, daidzein 4',7-di-O-sulfate (M-I), daidzein 7-0- $\beta$ -D-glucuronide (M-II), daidzein 4'-0-sulfate (M-III), daidzein (M-IV), as determined from spectroscopic and chemical data. Total cumulative amts. of the puerarin and four metabolites excreted in the urine at 48 h following the oral administration of puerarin were approx. 3.6% the doses administered. The bile of rats administered puerarin orally contained puerarin and two major metabolites, which were identified as puerarin 4'-0-sulfate (PB1) and puerarin  $7\text{--}0\text{--}\beta\text{--}\text{D--glucuronide}$  (PB2) on the basis of chemical and spectroscopic data. These exptl. data suggest that C-glycoside puerarin is partially hydrolyzed to aglycon in the body, but mainly excreted in the urine as unchanged puerarin.

163128-95-8 163128-96-9

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative) (puerarin urinary and biliary metabolites)

RN 163128-95-8 CAPLUS

4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-hydroxy-3-[4-CN (sulfooxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 163128-96-9 CAPLUS

CN  $\beta$ -D-Glucopyranosiduronic acid,  $8-\beta-\text{D-glucopyranosyl-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl}$ 

## (CA INDEX NAME)

Absolute stereochemistry.

- ANSWER 62 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN T. 9
- ΑN 1994:8844 CAPLUS
- DN 120:8844

OREF 120:1949a,1952a

- The rotational isomers of peracetylated C-glycosylflavonesTΤ
- ΑU
- Kato, Takeshi; Morita, Yutaka Fac. Pharm. Sci., Josai Univ., Sakado, 350-02, Japan CS
- Heterocycles (1993), 35(2), 965-73 CODEN: HTCYAM; ISSN: 0385-5414 SO
- DТ Journal
- LΑ English
- AΒ In 1H and 13C NMR of peracetylated 8-C- and 6-C-glycosylflavones, the signal doublings were observed due to the restricted rotation of the acetylated glucosyl moiety. The conformations of rotational isomers of hepta-O-acetylvitexin and octa-O-acetylorientin were decided as +sp (major) and -s.c. (minor) for both compds. by NMR (CDCl3) spectral data. The characteristic chemical shift phenomena in NMR of glycosylflavonoid could be applicable to differentiate 8-C-glucoside from 6-C-glucoside.
- ΙT 2889-07-8

RL: PRP (Properties)

(conformation of, NMR in relation to)

- RN 2889-07-8 CAPLUS
- 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-4)tetra-O-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)

- ANSWER 63 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 1993:525006 CAPLUS 1.9
- AN
- 119:125006
- OREF 119:22302h,22303a
- The solubility and complex-solubilization of puerarin TT
- Wang, Cheng; Liu, Yuling; Su, Shijie

## 10/563,471

CN

CS Inst. Materia Med., Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep. SO Zhongguo Yaoxue Zazhi (Beijing, China) (1993), 28(5), 294-6 CODEN: ZYZAEU; ISSN: 1001-2494  $\mathsf{DT}$ Journal LΑ Chinese The solubility of puerarin in aqueous solns. was increased with pH values at pH  $\geq 7.5$  and in the presence of methoxypuerarin. Amino acids (e.g. AB the solubility of puerarin, which may be used as solubilizers in the formulation of puerarin injections. 92117-94-7 TΤ RL: BIOL (Biological study) (puerarin solubility in aqueous solution increase by) RN 92117-94-7 CAPLUS

4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-hydroxy-3-(4-

Absolute stereochemistry.

methoxyphenyl) - (CA INDEX NAME)

ANSWER 64 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN T. 9 AN 1993:251489 CAPLUS DN 118:251489 OREF 118:43583a,43586a Leguminous plants . XXXIX. Three new isoflavonoid glycosides from Lupinus luteus and L. polyphyllus + arboreus Watanabe, Kazutaka; Kinjo, Junei; Nohara, Toshihiro ΑU Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, 862, Japan Chemical & Pharmaceutical Bulletin (1993), 41(2), 394-6 CS SO CODEN: CPBTAL; ISSN: 0009-2363 DT Journal English LΑ From Lupinus luteus and L. polyphyllus + arboreus hybrid, three new AB isoflavonoid glycosides were isolated together with six known ones. new compds. were: 8-C-glucopyranosylgenistein 4'-O-glucopyranoside, 5-O-methylgenistein 4',7-di-O-glucopyranoside, and 2'-hydroxygenistein 4',7-di-O-glucopyranoside. The isoflavonoid distributions in the two species were differed. 147879-67-2 RL: BIOL (Biological study) (from Lupinus species and hybrids, isolation and structure of) RN 147879-67-2 CAPLUS 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-3-[4-( $\beta$ -Dglucopyranosyloxy) phenyl] -5, 7-dihydroxy- (CA INDEX NAME)

```
L9
      ANSWER 65 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
      1991:542430 CAPLUS
AN
      115:142430
DN
OREF 115:24295a,24298a
TΙ
      Determination of 4'-methoxy-puerrarin in puerrarin by reversed phase HPLC
      Xu, L. X.; Zhang, X. Q.; Liu, A. R.
Inst. Materia Med., Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep.
ΑU
CS
      China
      Yaoxue Xuebao (1991), 26(6), 475-9
CODEN: YHHPAL; ISSN: 0513-4870
DT
      Journal
LΑ
      English
      A reversed-phase HPLC based on a LiChrosorb Rp-18 column and EtOH-H2O
      (10:90) mobile phase was developed for determination of 4'-methoxypuerarin (I) in
      quality control of puerarin. A linear relation was found between the ratio of peak height and the amount of I over the range 0.8-2.5 \mu g.
      Recoveries were 93.2-97.5%.
      92117-94-7, 4'-Methoxypuerarin
RL: ANT (Analyte); ANST (Analytical study)
ΙT
          (determination of, in puerarin, by HPLC)
      92117-94-7 CAPLUS
      4H-1-Benzopyran-4-one, 8-\beta-D-glucopyranosyl-7-hydroxy-3-(4-methoxyphenyl)- (CA INDEX NAME)
CN
```

```
L9 ANSWER 66 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1991:244252 CAPLUS
DN 114:244252
OREF 114:41153a,41156a
TI Dalpaniculin, a C-glycosylisoflavone from Dalbergia paniculata seeds
AU Rao, J. Rajasekhara; Rao, R. Srinivasa
CS Post-Grad. Cent., Sri Venkateswara Univ., Cuddapah, 516 004, India
```

## 10/563,471

- SO Phytochemistry (1991), 30(2), 715-16
  CODEN: PYTCAS; ISSN: 0031-9422
  DT Journal
  LA English
  GI
- HO OME OME OME OME

AB Further examination of seeds of D. paniculata has yielded (+)-pinitol, caviunin 7-0-rhamnoglucoside, isocaviunin 7-0-glucoside and two new compds.: a C-glycosylisoflavone, dalpaniculin (I, Glc =  $\beta$ -D-glucopyranosyl), and an 0-glycosyldehydrotenoid, dehydrodalpanol 0-glucoside (II). 

II 133956-26-0, Dalpaniculin RL: PROC (Process) (from Dalbergia paniculata, mol. structure determination of) 

RN 133956-26-0 CAPLUS 
CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-5,7-dihydroxy-6-methoxy-3-(2,4,5-trimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.

- ANSWER 67 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN  $1988\!:\!576147$  CAPLUS L9
- ΑN
- 109:176147 DN
- OREF 109:29103a,29106a
- Isolation and high performance liquid chromatography (HPLC) of isoflavonoids from the Pueraria root
- Ohshima, Yukio; Okuyama, Toru; Takahashi, Kunio; Takizawa, Toshio; Shibata, Shoji ΑU
- CS Meiji Coll. Pharm., Tokyo, 154, Japan
- Planta Medica (1988), 54(3), 250-4 CODEN: PLMEAA; ISSN: 0032-0943
- DT Journal
- LAEnglish
- From the Chinese drug Gegen (the roots of P. lobata or P. pseudohirsuta), several isoflavonoid compds. were isolated. Besides the known compds. (puerarin, daidzin, daidzein, and formononetin), the presence of pueraria glycosides (PG) 1, 2, 3, and 6 and puerarol in the Pueraria root exts. was revealed by HPIC. The chemical structures of PG-1, 2, 3, and 6 as well as puerarol were supported by spectral data.
- 117047-08-2 ΤТ
  - RL: BIOL (Biological study) (from Pueraria lobata roots)
- RN 117047-08-2 CAPLUS
- 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-3-[4-( $\beta$ -D-CN glucopyranosyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

116994-28-6P 117008-18-1P 117047-05-9P

Absolute stereochemistry.

RN 117008-18-1 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-methoxy-3-(4-methoxyphenyl)-8-(6-0- $\beta$ -D-xylopyranosyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 117047-05-9 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-8-(2,3,4,6-tetra-0-acetyl- $\beta$ -D-glucopyranosyl)-3-[4-[(2,3,4,6-tetra-0-acetyl- $\beta$ -D-glucopyranosyl)oxy]phenyl]- (CA INDEX NAME)

RN 117047-08-2 CAPLUS CN 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-3-[4-( $\beta$ -D-glucopyranosyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.

RN 117047-09-3 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[3,4-bis(acetyloxy)phenyl]-8(2,3,4,6-tetra-0-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 117047-10-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-(3,4-dimethoxyphenyl)-8- $\beta$ -D-glucopyranosyl-7-methoxy- (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 68 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1984:537094 CAPLUS

DN 101:137094

OREF 101:20757a,20760a

TI HPLC determination of isoflavones in Ge Gen (Radix Puerariae) and its

AU Zhang, Yuzhong; Yang, Fan

CS Inst. Chin. Mater. Med., Acad. Tradit. Chin. Med., Peop. Rep. China

SO Yaowu Fenxi Zazhi (1984), 4(2), 67-70

CODEN: YFZADL; ISSN: 0254-1793

DT Journal

LA Chinese

AB Daidzein 4',7-diglucoside [53681-67-7], puerarin [3681-99-0],
4'-methoxypuerarin [92117-94-7], daidzin [552-66-9] and
daidzein [486-66-8] in Ge Gen (Puerariae roots) or their tablets were
determined by HPLC (Zorbax ODS as stationary phase; MeOH-H2O (32:68) as mobile
phase). As an example, 0.1 g powder was extracted with 70% EtoH (10 mL), and
1 mL of the extract was diluted with MeOH with addition of internal standard A
0.6-μL solution was subjected to anal. by HPLC. The retention time was
7.94, 12.97, 14.29, 20.09 and 53.76 min, resp. Contents of various
isoflavones in roots of P. lobata from various locations in China ranged
0.0155-2.002, 0.108-5.749, 0.2411-1.908, 0.0175-1.393 and 0.049-0.155%,
resp. No pretreatment of crude samples was required. The method was
simple and rapid and only a small amount of samples was required in anal.

RN

CN

RL: ANT (Analyte); ANST (Analytical study) (determination of, in Pueraria roots and their tablet prepns. by HPLC) 92117-94-7 CAPLUS 4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-hydroxy-3-(4methoxyphenyl) - (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 69 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 1979:138107 CAPLUS T. 9

AN

90:138107 DN

OREF 90:21913a,21916a

C-glycosylflavonoids. II. The synthesis of 7,4'-di-O-methylpuerarin (8-C- $\beta$ -D-glucopyranosyl-7,4'-dimethoxyisoflavone) Eade, Ronald A.; McDonald, Francis J.; Huu Phung Pham Sch. Chem., Univ. New South Wales, Keningston, Australia Australian Journal of Chemistry (1978), 31(12), 2699-706 CODEN: AJCHAS: ISSN: 0004-9425 TΙ

ΑU

CS SO

CODEN: AJCHAS; ISSN: 0004-9425

DT Journal

English LΑ

GT

The product of reaction of 2'-acetoxy-4,4'-dimethoxy-3'-(tetraacetyl-AΒ GP-D-glucopyranosyl)chalcone (I) with T1(NO3)3 in MeOH-CH(OMe)3 solution gave, after acid hydrolysis, a high yield of 7,4'-di-O-methylpuerarin (II). The di-Me acetal (III) and the enol ether (IV) were isolated from the reaction of I with Tl(NO3)3 in MeOH. Both III and IV gave II on reaction with acid or base.

69655-50-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and oxidative rearrangement of, puerarin derivative from)

69655-50-1 CAPLUS

4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-7-methoxy-3-(4methoxyphenyl) - (CA INDEX NAME)

69655-53-4P ΙT

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

69655-53-4 CAPLUS RN

4H-1-Benzopyran-4-one, 7-methoxy-3-(4-methoxyphenyl)-8-(2,3,4,6-tetra-0-CN  $acetyl-\beta-D-glucopyranosyl)-$  (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 70 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 1978:101558 CAPLUS T. 9

AN

DN 88:101558

OREF 88:15897a,15900a

The C-flavonosides from Sarothamnus scoparius. Isolation of a new TΙ compound, 6-0-acetylscoparoside

Brum-Bousquet, Michele; Tillequin, Francois; Paris, Rene Raymond Lab. Matiere Med., Fac. Sci. Pharm. Biol., Paris, Fr. Lloydia (1977), 40(6), 591-2 CODEN: LLOYA2; ISSN: 0024-5461 ΑU

CS

SO

DT Journal

LA French

GΤ For diagram(s), see printed CA Issue.

AB From S. scoparius leaves genitoside, scoparoside and 5 other flavones, which upon acid and alkaline hydrolysis yielded acyl and O-heteroside scoparoside derivs. One of the acrylic C-glycosylflavones was identified as 6''-O-acetylscoparoside (I).

24562-39-8P ΤТ

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

24562-39-8 CAPLUS RN

4H-1-Benzopyran-4-one,  $8-(6-0-acetyl-\beta-D-glucopyranosyl)-3-[4-benzopyranosyl)$ CN(acetyloxy) phenyl] -7-hydroxy- (CA INDEX NAME)

## 10/563,471

```
ANSWER 71 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
Ь9
      1977:5750 CAPLUS
ΑN
DN
      86:5750
OREF 86:1003a,1006a
      TLC separation and identification of some flavonoid C-glycosides
TΤ
      Chawla, H. M.; Chibber, S. S. Dep. Chem., Univ. Delhi, Delhi, India Chromatographia (1976), 9(8), 408-9 CODEN: CHRGB7; ISSN: 0009-5893
ΑU
CS
SO
DT
      Journal
LΑ
      English
      Thin-layer chromatog. on silica gel plates provides a method for the quant. separation and identification of isomeric flavone and isoflavone
AΒ
      C-glycosides.
      52448-12-1 58930-58-8
      RL: ANT (Analyte); ANST (Analytical study)
           (chromatog. of)
RN
      52448-12-1 CAPLUS
      4H-1-Benzopyran-4-one, 8-\beta-D-glucopyranosyl-5-hydroxy-3-(4-
      hydroxyphenyl)-7-methoxy- (CA INDEX NAME)
```

Absolute stereochemistry.

RN 58930-58-8 CAPLUS
CN 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-5,7-dihydroxy-6-methoxy-3(4-methoxyphenyl)- (CA INDEX NAME)

ANSWER 72 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN  $1976\!:\!577876$  CAPLUS T. 9 ΑN DN85:177876 OREF 85:28447a,28450a New isoflavonoid glycosides fom Dalbergia paniculata TΤ ΑU Parthasarathy, Madhanam R.; Seshadri, Tiruvenkata R.; Varma, Rajender S. Dep. Chem., Univ. Delhi, Delhi, India Phytochemistry (Elsevier) (1976), 15(6), 1025-7 CODEN: PYTCAS; ISSN: 0031-9422 CS SO DT Journal LΑ English The methanolic extract of the bark of D. paniculata gave 3 isoflavonoid AΒ glycosides 8-C-glucopyranosylpruetin and biochanin A and formononetin 7-rutinosides. 52448-12-1 RL: RCT (Reactant); RACT (Reactant or reagent) (of Dalbergia paniculata, structure of) 52448-12-1 CAPLUS


4H-1-Benzopyran-4-one,  $8-\beta$ -D-glucopyranosyl-5-hydroxy-3-(4-

hydroxyphenyl)-7-methoxy- (CA INDEX NAME)

Absolute stereochemistry.

CNmethoxyphenyl) - (CA INDEX NAME)

Absolute stereochemistry.



IT 58930-61-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation of)

RN 58930-61-3 CAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-3-(4-methoxyphenyl)-8-(2,3,4,6-tetra-0-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

McIntosh

4H-1-Benzopyran-4-one, 5,7-bis(acetyloxy)-6-methoxy-3-(4-methoxyphenyl)-8-(2,3,4,6-tetra-0-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

- L9 ANSWER 74 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
- ΑN 1974:105902 CAPLUS
- 80:105902 DN
- OREF 80:17019a,17022a
- Minor isoflavonoid glycosides of the stem bark of Dalbergia paniculata. Isolation of a new C-glycoside
- ΑU
- CS
- Parthasarathy, M. R.; Seshadri, T. R.; Varma, R. S. Chem. Dep., Univ. Delhi, Delhi, India Current Science (1974), 43(3), 74-5 CODEN: CUSCAM; ISSN: 0011-3891 SO
- DT Journal
- LA English
- AΒ The bark of D. paniculata was shown to contain minor glycosides sissotrin (biochanin 7-0-qlucoside), formononetin 7-0-qlucoside, and 8-C-qlucosyl prunetin.
- ΤТ 52448-12-1
  - RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence) (of Dalbergia paniculata)
- 52448-12-1 CAPLUS RN
- 4H-1-Benzopyran-4-one, 8- $\beta$ -D-glucopyranosyl-5-hydroxy-3-(4hydroxyphenyl)-7-methoxy- (CA INDEX NAME)

- 52448-13-2P ΙT
  - RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
- RN 52448-13-2 CAPLUS
- 4H-1-Benzopyran-4-one, 5-(acetyloxy)-3-[4-(acetyloxy)phenyl]-7-methoxy-8-CN (2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)

# 10/563,471

Absolute stereochemistry.

- ANSWER 75 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN 1973:475539 CAPLUS L9
- AN
- DN79:75539
- OREF 79:12229a,12232a
- Method to differentiate isomeric C-glucosyl chromones, isoflavones, and TΙ xanthones
- ΑU Holdsworth, David K.
- CS Dep. Chem., Univ. Papua and New Guinea, Boroko, Papua New Guinea
- Phytochemistry (Elsevier) (1973), 12(8), 2011-15 CODEN: PYTCAS; ISSN: 0031-9422 SO
- DТ Journal
- LΑ English
- AΒ Isomeric 6-C- and 8-C-glucosyl chromones and isoflavones can be readily distinguished by a study of the NMR signals of their acetates. In a similar manner 2-C- and 4-C-glucosylxanthones can be distinguished.
- 2889-07-8 49584-90-9 RL: PRP (Properties)
  - (NMR of)
- 2889-07-8 CAPLUS RN
- 4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-)tetra-O-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

- RN 49584-90-9 CAPLUS
- 4H-1-Benzopyran-4-one, 5,7-bis(acetyloxy)-3-[4-(acetyloxy)phenyl]-6,8-CN bis(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME)

```
L9
     ANSWER 76 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
     1973:58735 CAPLUS
ΑN
DN
     78:58735
OREF 78:9327a,9330a
     Isoflavonoid glycosides of Dalbergia paniculata. Constitutions of
TΙ
     dalpanitin and dalpatin
     Adinarayana, D.; Rao, J. Rajasekhara
Dep. Chem., Sri Venkateswara Univ., Tirupati, India
Tetrahedron (1972), 28(21), 5377-84
CODEN: TETRAB; ISSN: 0040-4020
ΑU
CS
SO
DТ
     Journal
LΑ
     English
GI
     For diagram(s), see printed CA Issue.
     Three isoflavonoid glycosides, dalpanitin (I) and dalpatin (II) and
AB
     dalpanin (III) were isolated from the seeds of D. paniculata. The
     structures of I and II were assigned on spectral and chemical evidence. III
     was identical with that extracted from the flowers of D. paniculata (A.;
     R.; 1972).
     40009-86-7P 40009-87-8P
ΙT
     RL: SPN (Synthetic preparation); PREP (Preparation)
         (preparation of)
     40009-86-7 CAPLUS
RN
CN
     4H-1-Benzopyran-4-one, 5,7-bis(acetyloxy)-3-[4-(acetyloxy)-3-
     methoxyphenyl]-8-(2,3,4,6-tetra-0-acetyl-\beta-D-glucopyranosyl)- (CA
     INDEX NAME)
```

RN 40009-87-8 CAPLUS CN 4H-1-Benzopyran-4-one, 3-(3,4-dimethoxyphenyl)-5,7-dimethoxy-8-(2,3,4,6-tetra-0-acetyl- $\beta$ -D-glucopyranosyl)- (CA INDEX NAME)

```
ANSWER 77 OF 79 CAPLUS COPYRIGHT 2009 ACS on SIN
Ь9
                 1969:413322 CAPLUS
AN
DN
                  71:13322
OREF 71:2459a,2462a
TΙ
                 Components of the roots of Pueraria tuberosa: isolation of a new
                  isoflavone C-glycoside (di-O-acetylpuerarin)
                 Bhutani, S. P.; Chibber, Shyam S.; Seshadri, Tiruvenkata R. Univ. Delhi, Delhi, India
ΑU
CS
SO
                 Indian Journal of Chemistry (1969), 7(3), 210-12
                 CODEN: IJOCAP; ISSN: 0019-5103
DT
                 Journal
                 English
LA
AΒ
                 The roots of P. tuberosa contain \beta-sotosterol and stigmasterol in the
                 petroleum ether extract and daidzein in the ether extract In the alc. extract of
                 the roots, besides daidzin and puerarin, a new isoflavone C-glycoside was
                 isolated, whose constitution was established as 4',6''-Di-O-acetylpuerarin.
                 24562-39-8P
                 RL: PREP (Preparation)
                            (from Pueraria tuberosa)
                 24562-39-8 CAPLUS
RN
                  4H-1-Benzopyran-4-one, 8-(6-0-acetyl-\beta-D-glucopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl)-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-Benzopyranosyl]-3-[4-1-
                  (acetyloxy)phenyl]-7-hydroxy- (CA INDEX NAME)
```

```
L9 ANSWER 78 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1965:459703 CAPLUS
DN 63:59703
OREF 63:10885h,10886a
TI Nuclear magnetic resonance studies. III. Rotational isomerism of some c-glucosyl flavonoid acetates
AU Eade, R. A.; Hillis, W. E.; Horn, D. H. S.; Simes, J. J. H.
CS Univ. New South Wales, Sydney
```

```
SO
     Australian Journal of Chemistry (1965), 18, 715-21
     CODEN: AJCHAS; ISSN: 0004-9425
DT
    Journal
T.A
    English
AB
     cf. CA 63, 4380f. The proton resonance spectra of certain c-glucosyl
     flavonoid acetates are temperature dependent. For example, bayin hexaacetate
     exists in 2 distinct isomeric forms at 0° owing to the steric
     effect of bulky substituent sugar and aromatic groups. The rate of
     interconversion of isomers increases with temperature and is rapid at
     60°. Differences in orientation and position of the Ac and Ph
     groups cause the proton diamagnetic shielding consts. of the 2 isomers to
     be different, leading to their identification.
     2889-07-8, Puerarin, hexaacetate
        (rotational isomerism in, nuclear magnetic resonance absorption of)
RN
     2889-07-8 CAPLUS
     4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-1)
CN
     tetra-O-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)
```

```
ANSWER 79 OF 79 CAPLUS COPYRIGHT 2009 ACS on STN
L9
     1965:424425 CAPLUS
AN
DN
     63:24425
OREF 63:4380f-h
ТΙ
     Nuclear magnetic resonance spectra and structures of some
     C-qlycosylflavonoids
ΑIJ
     Hillis, W. E.; Horn, D. H. S.
     Div. Forest Prod., C.S.I.R.O., Melbourne
Australian Journal of Chemistry (1965), 18(4), 531-42
CS
     CODEN: AJCHAS: ISSN: 0004-9425
DТ
     Journal
LA
     English
     N.M.R. spectra, optical rotations, and other properties of some flavonoid
     C-glycosides, their acetates, and related model compds. have been used to
     determine their structures. Proton chemical shift and coupling constant data are
     given for vitexin, vitexin tetraacetate, vitexin heptaacetate,
     saponaretin, saponaretin hexaacetate, apigenin apigenin triacetate, bayin,
     bayin hexaacetate, 7,4'-dimethoxybayin tetraacetate,
      4'-methoxy-7-acetoxyflavone, puerarin, puerarin hexaacetate, daidzein
     diacetate, isohemiphloin, isohemiphloin hexaacetate, isohemiphloin heptaacetate, hemiphloin, hemiphloin hexaacetate, hemiphloin heptaacetate,
     naringenin, naringenin triacetate,
     penta-O-acetyl-\beta-D-glucopyranoside, 2'',3'',4'',6''-tetra-O-acetyl-\beta-D-glycopyranosylbenzene, and
     dihydrobenzoin diacetate. It is concluded that vitexin, bayin, puerarin,
     and isohemiphloin are C-\beta-D-glycosides with the sugar substituent in the 8-position of the flavoid nucleus. Hemiphloin and saponaretin are 2
     of the corresponding 6-substituted compds. In hemiphloin and
      isohemiphloin the Ph B ring has the equatorial configuration.
TT
     2889-07-8, Puerarin, hexaacetate
         (NMR and structure of)
     2889-07-8 CAPLUS
      4H-1-Benzopyran-4-one, 7-(acetyloxy)-3-[4-(acetyloxy)phenyl]-8-(2,3,4,6-
     tetra-O-acetyl-β-D-glucopyranosyl)- (CA INDEX NAME)
```